Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: (rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Randomized , Phase 2, Double-blind, Placebo-controlled Study to 
Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 
in Adult Subjects with Active Sjogren's Syndrome 
[COMPANY_009] Sciences , Inc. 
[ADDRESS_1035995] 
Foster City, CA [ZIP_CODE] 
[LOCATION_003] 
123903 
2016 -003 558-34 
[STUDY_ID_REMOVED] 
Sjogren's Syndrome 
GS-US-445-4189 
[COMPANY_009] Clinical Name: [CONTACT_756958]: Telephone : 
[COMPANY_009] Medical Name: 
[CONTACT_580889]: Telephone : 
Fax: 
Mobi le: 
Protocol Version/Date: Original: 
Amendment 1: PD 
PD 
PD PD 
[ADDRESS_1035996] O F IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. Filgotinib ................................................................................................................................................ 17
1.2.1. Nonclinical Pharmacology and Toxicology ......................................................................... 17
1.2.2. Clinical Trials of Filgotinib .................................................................................................. 18
1.3. GS-9876 ................................................................................................................................................. 18
1.3.1. Nonclinical Pharmacology and Toxicology ......................................................................... 18
1.3.2. Clinical Trials of GS -9876 ................................................................................................... 20
1.4. GS-4059 ................................................................................................................................................. 21
1.4.1. Nonclinical Pharmacology and Toxicology ......................................................................... 21
1.4.2. Clinical Trials of GS -4059 ................................................................................................... 23
1.5. Rationale for Current Study ................................................................................................................... 23
1.6. Rationale for Dose Selection .................................................................................................................. 25
1.7. Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_1035997] Study Care ...................................................................................................................................... 34
3.7. Biomarker Testing .................................................................................................................................. 34
3.7.1. Biomarker Samples to Address the Study Objectives: ......................................................... [ADDRESS_1035998] Enrollment and Treatment Assignment ..................................................................................... 49
6.2. Pretreatment Assessments ...................................................................................................................... 49
6.2.1. Screening Visit ..................................................................................................................... 49
6.2.2. Day 1 Assessments ............................................................................................................... 51
6.3. Randomization ..............................................................................................................................
......... 53
6.4. Week 2 and Week 26 ............................................................................................................................. 53
6.5. Week 4 ................................................................................................................................................... 54
6.6. Week 8 ................................................................................................................................................... 56
6.7. Week 12 ................................................................................................................................................. 57
6.8. Week 18 ................................................................................................................................................. 59
6.9. Week 24 ................................................................................................................................................. 61
6.10. Week 28 ................................................................................................................................................. 63
6.11. Week 32 ................................................................................................................................................. 64
6.12. Week 36 ................................................................................................................................................. 65
6.13. Week 42 ................................................................................................................................................. 67
6.14. Week 48/Early Termination (ET) ........................................................................................................... 68
6.15. Follow -up Visit ...................................................................................................................................... 70
6.16. Study Assessments ................................................................................................................................. 70
6.16.1. Patient Reported Outcomes: Visual Analogue Scales and Questionnaires .......................... 71
6.16.2. Physician Reported Outcomes: Visual Analogue Scales, Joint Exam and 
Disease Activity Index ......................................................................................................... [ADDRESS_1035999] (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... [ADDRESS_1036000] Accountability and Return ............................................. 96
9.1.8. Inspections ............................................................................................................................ 97
9.1.9. Protocol Compliance ............................................................................................................ 97
9.2. Sponsor Responsibilities ........................................................................................................................ 97
9.2.1. Protocol Modifications ......................................................................................................... 97
9.2.2. Study Report and Publications ............................................................................................. 97
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 98
9.3.1. Payment Reporting ............................................................................................................... 98
9.3.2. Access to Information for Monitoring .................................................................................. 98
9.3.3. Access to Information for Auditing or Inspections .............................................................. 98
9.3.4. Study Discontinuation .......................................................................................................... 98
10. REFERENCES ................................................................................................................................................... 99
11. APPENDICES .................................................................................................................................................. 102
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................. 103
Appendix 2. Schedule of Assessments Table ............................................................................................ 104
Appendix 3. Management of Clinical and Laboratory Adverse Events .................................................... 109
Appendix 4. Common Terminology Criteria for Ad verse Events (CTCAE) v4.03 .................................. 110
Appendix 5. Pregnancy Precautions, Definition of Female of Childbearing Potential, and 
Contraceptive Measures ....................................................................................................... 111
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 5 12July2018Appendix 6. Laboratory Assessment Table .............................................................................................. 114
Appendix 7. American European Consensus Group (AECG) .................................................................. 115
Appendix 8. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) ........................................ [ADDRESS_1036001] OF IN -TEXT TABLES
Table 1-1. Margins for GS -9876 Based on Systemic Exposure Relative to the Observed 
Human Exposure at 30 mg o nce daily (AUC) ........................................................................ 20
Table 1-2. Margins for GS -4059 Based on Systemic Exposure Relative to the Observed 
Human Exposure at 40 mg o nce daily (AUC) ........................................................................ [ADDRESS_1036002]
Foster City, CA [ZIP_CODE]
[LOCATION_003]
Study Title: A Randomized, Phase 2, D ouble -blind, Placebo -controlled Study 
to Assess the Safet y and E fficacy  of Filgotinib, GS -9876 and GS -
4059 in Adult S ubjects with Active Sjogren’s Sy ndrome
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_5795]-003558-34
[STUDY_ID_REMOVED]
Study Centers Planned: Approximately  60-80 c enters globally
Objectives: The primary objective of this study  is:
To assess the efficacy  of filgotinib , GS-9876, and GS- 4059 in
adult subjects with active Sjogren’s S yndrome ( SjS)
The secondary  objectives of this study  are:
To assess the safet y and tolerability of filgotinib , GS-
9876,
andGS-
4059 inactive Sj S
To assess the effect of filgotinib , GS-9876 and GS -4059 on 
patient reported outcomes in active SjS
The exploratory  objectives of this study  are:
CCI
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445-4189 Final 
[COMPANY_009] Sciences , Inc. Amendment 1 
Study Design: This will be a multicenter , randomized, double-blind , 
placebo-c ontrolled study to evaluate the safety and efficacy of 
filgotinib , GS-9876, and GS-[ADDRESS_1036003] s with active SjS. Eligible subjects will be randomized 
Number of Subjects 
Plalllled: 
CONFIDENTIAL 1: 1: 1: 1 to daily oral filgotinib (200 mg), or GS-987 6 (30 mg), or 
GS-4059 ( 40 mg) or placeb o to match (PTM). Rand omizat ion will 
be stratified by: [CONTACT_756932]1y drngs at 
baseline (YIN: conventional synthetic disease modifyin g 
anti.rheumatic drugs ( csDMARD[ s]) or corticosteroids) , and the 
hemato logic + biological component scores of the EULAR 
Sjog ren's syndrome disease activity index (ESSDAI) obtained at 
scree ning ( combined score of <2 or~ 2). Stable medications at 
Day 1 should be continued during the study dosing period. Dose 
adjustments for toxicities and dose adjustment of corticosteroids 
after Week 12 a.re outlined in Section 5.8. 
At the Week 24 visit, subjects on placebo will be re-randomized 
1: 1: 1, in a blinded fashion, to daily oral filgotinib (200 mg), 
GS-9876 (30 mg), or GS-4059 (40 mg) without fmiher 
strati ficati on. Dosing and assessments for all subjects will continue 
through Week 48. 
Subjects who intenupt or pennanently discontinue study drng 
dosing will continue the study visits, procedures , and assessments, 
if deemed medically a 'ppro priate by [CONTACT_093]. 
Screening 
28 days Day l 
Placebo Week24 
Filgotinib 
200mgQD 
GS-9876 
30mgQD 
GS-4059 
40mgQD 
Filgotinib 200 mg QD 
GS-9876 30 mg QD 
GS-4059 40 mg QD 
Approximately 140 adult subjects with active SjS 
Page 7 Week48 
FU visit 
4we-eks 
aftH 
dose- of 
study 
d.-ug 
12 July 2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 8 12July2018Target Population: Male and female subjects with active SjS between 18 and 75 years 
of age (inclusive) at the time of consent 
Duration of Treatment: Up to 48 week s of dosing
Diagnosis and Main 
Eligibility  Criteria:Subjects must meet the all eligibility  criteria participate in this 
study .For a complete list of study  inclusion and exclusion criteria, 
please refer to Sections 4.2and 4.3, respectivel y .
Male or female subjects between 18and 75 years of age
(inclusive)
Diagnos edwith SjSaccording to American European 
Consensus Group ( AECG )classification
Active SjS as defined b y anESSDAI  ≥5
Seropositivity  for antibodies to SjS -associated antigens A and 
B (
anti-SSA or anti- SSB)
No concurrent treatment with any  bDMARD (washout as 
perprotocol Section 5.8)
Study  Procedures/
Frequency :Participating subjects will visit the clinical study  center at 
Screening, 
Day 1, Weeks 2, 4, 8, 12, 18, 24, 26, 28, 32, 36, 42 and
48or earl y termination (ET)plus follow up visit .
At Day 1, after the subject’s eligibility  for the study  has been 
confirmed , the subject will be randomized into the study  to receive 
filgotinib (200 mg), GS -9876 (30 mg), GS-
4059 (40mg), or PTM.
Screening and o n-treatment assessments will include: Vital Signs, 
Physical Examination (PE), [ADDRESS_1036004] igator’s Assessment of Sj S disease activity , Investigator’s 
global assessment of concomitant Rheumatoid Arthritis
(RA)or 
Systemic Lupus Ery thematosus (SLE)disease activity  (as
applicable), ESSDAI, urine drug screen , 
pregnancy  test (as
applicable), , TB testing, 
chest X- ray (CXR as applicable), CD19+ B cell count (as 
applicable), HbA1c, Thyroid -Stimulating Hormone (TSH) , 
hematology , Erythrocy te Sedimentation Rate (ESR) as available, 
chemistry  and hsCRP, viral serology and viral monitoring ( as 
applicable ), autoantibodies , complement , immunoglobulins, fasting 
lipid profile, , Patient Reported Outcome (PRO) 
questionnaires and Visual Analogue Scales (VAS), Pulmonary  
Function Test (PFT as available ),  
s test, concomitant medications, Adverse 
Events (AEs) , and a t available sites: m  
CCI
CCI
CCI
CCI
Filgotinib , GS-[ADDRESS_1036005] , Dose, and 
Mode of Admini stration: 
Reference Therap y, Dose, 
and Mode of 
Admini stration: 
Criteria for Evaluation: 
Safety: 
Efficacy: 
CON FIDENTIAL Final 
Amendmen t 1 
A resting 12-lead ECG shou ld be perfonned at Scree ning, Day 1, 
Weeks 2, 8, 12, 24, 26, 32, 36 and 48 or ET. E CGs shou ld be 
inte1 p reted by [CONTACT_093] ( or quali fied designee) for clinical 
significance. 
Post treatme nt follow -up assess ments include AEs, concomitant 
medicatio ns, physical examination , 12-lead ECG , vital signs , 
blood and urine sampling for safety laborat01y tests, and urine 
pregnancy tests (if applicable). 
Filgotinib 200 mg (1 x 200 mg tablet) , admini stered orally 
once daily 
GS-9876 30 mg (1 x 30 mg tablet) , admini stere d orally once daily 
GS-4059 40 mg (1 x 40 mg tablet) , admini stere d orally once daily 
PTM filgotinib (1 x placebo tablet), admin istered orally once daily 
PTM GS-9876 (1 x placebo tablet) , administered orally once daily 
PTM GS-4059 (1 x placebo tablet) , administered orally once daily 
Safety will be assessed through the repo1iing of AEs, clinical 
laborato1y tests, PEs, vital sign assessme nts, and ECGs at various 
time points during the study. 
The primaiy endpoint is the propo1iio n of subjects fulfilling 
protocol-spec ified respo nse criteria at Week 12, as compared to 
baseline. 
Respo nse is defined as follows: 
Page9 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 10 12July2018For subjects with elevated hsCR P (defined as ≥ 1.5 upper limit 
of normal 
(ULN )of hsCRP) at Day  1, subjects are considered 
to be a responder if they  achieve all of the following :
-≥ 20% improvement in hsCRP
- ≥ 20% improvement in at least [ADDRESS_1036006] reported, 
SjS related visual an alog scales (VAS; subject’s assessment 
of global disease, pain, oral dry ness, ocular dry ness and 
fatigue)
-
no worsening (defined as > 30 mm increase from baseline) 
in any  of the above VAS
For subjects without elevated hsCRP (< 1.[ADDRESS_1036007] of hsCRP) 
atDay 1, subjects are considered to be a responder if achieve 
all of 
the following:
- no increase ≥ 1.[ADDRESS_1036008] of hsCRP
-
≥20% improvement in at least [ADDRESS_1036009] reported, 
SjS related VAS ( subject’s assessment of global disease, 
pain, oral dry ness, ocular dry ness and fatigue)
- no worsening (defined as > 30 mm increase from baseline) 
in any  of the above VAS
Secondary  endpoints include: the change in ESSDAI and in
ESSPRI  from baseline to Week 12 and 24
Pharmacokinetics: Plasma 
concentrations of filgotinib (and its m etabolite 
GS-829845), GS - 9876, andGS- 4059 will be listed and 
summarized using descriptive statistics.
Statistical Methods: The primary  anal ysis set for efficacy  anal yses will be the Full 
Analy sis Set (FAS), which includes all randomized subjects who 
received at least one dose of study  drug.
The primary  endpoint is the proportion of subjects fulfilling 
response criteria as outlined above . The primary  anal ysis will 
consist of a superiorit y test of each of filgotinib, GS -[ADDRESS_1036010] bo, respectivel y. Cochran Mantel Haenszel 
(CMH )approach adjust edfor the randomization stratification 
factors will be used for the hy pothesis testing at the 2 -sided 0.05-
level.
Based on results of prior SjSstudies, assuming a response rate of 
70% for theactive arm and 30% for the placebo arm at Week 12, 
atleast 
35evaluable subjects will be needed in each arm to achieve 
85% power to detect a significant difference at a 2- sided, 
0.05- level. Therefore, a total of approximately  140 subjects are 
planned to 
be enrolled in the study .
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 11 12July2018All continuous endpoints will be summarized using an 8 -number 
summary  (n, mean, standard deviation [SD], median, 1stquartile 
[Q1], 3rdquartile [Q3], minimum, maximum) by  [CONTACT_756933]. All categorical endpoin ts will be summarized by  
[CONTACT_756934].
Safety  endpoints will be anal yzed by [CONTACT_204954] 
8-number summary  (n, mean, SD, m edian, Q1, Q3, minimum, 
maximum) for continuous data by  [CONTACT_756935].
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents .
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 12 12July2018GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
ADL Activities of Daily Living
AE(s) Adverse Event (s)
AECG American European Consensus Group
ALT Alanine Aminotransferase
Anti-SSA Anti-Sjogren’s -syndrome -related antigen A
Anti-SSB Anti-Sjogren’s -syndrome -related antigen B
ATP adenosine t riphosphate
AST Aspartate Aminotransferase
AUC 0-Ʈ Area under the plasma drug concentration -time curve of a dosing interval
AUROC Area Under R eceiver Operating Characteristic
BCR B
-cell receptor
bDMARD (s) Biologic Disease Modifying Antirheumatic Drug (s)
BLQ Below  the Limit of Quantitation
BTK Bruton’s tyrosine kinase
CƮ Trough plasma concentration (just before the next dosing ie pre- dose sample)
Cave Average observed concentration
CCP Cyclic citrullinated peptide
csDMARD(s) Conventional synthetic disease modifying antirheumatic drugs
CFR Code of Federal Regulations
CIA Collagen -Induced Arthritis
Cmax Maximum observed plasma concentration
CLE cutaneous l upus erythematosus
CMH Cochran Mantel Haenszel
CNS central nervous system
CRO Contract Research Organization
hsCRP High sensitivity C-Reactive Protein
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrom e P450
DAS28 Disease Activity Score based on [ADDRESS_1036011](s) Disease -Modifying Antirheumatic Drugs
DNA Deoxyribonucleic acid
EC 50 Half maximal effective concentration
ECG electrocardiogram
eCRF electronic Case Report Form
ESSDAI EULAR Sj ogren's syndrome disease activity index
ESSPRI EULAR Sjogren's Syndrom e Patient Reported Index
ET Early Term ination
EU European Union
Filgotinib, GS -[ADDRESS_1036012]
P-gp P-glycoprotein
PK Pharm acokinetics
PRO Patient Reported Outcome
PROFAD -SSI-SF Profile of Fatigue and Discomfort -Sicca Symptoms Inventory
PT Preferred Term
PTM Placebo To Match
PVE Pharm acovigilance and Epi[INVESTIGATOR_756914] ; once daily
QTc interval Corrected QT interval
RA Rheumatoid Arthritis
ROC Receiver Operating Characteristic
SAE (s) Serious Adverse Event (s)
SAP Statistical Analysis Plan
SF-36 Short -form health survey
SI International system of units
SjS Sjogren’s Syndrome
SLE Systemic Lupus Erythematosus
SOC System  Organ Class
STAT Signal Transducer and Activator of Transcription
SYK Spleen tyrosine kinase 
TB Tuberculosis
TBNK T-cells, B -cells and NK cells
TEAEs Treatment emergent adverse events
TFH Follicular B T helper cells
tmax Time of occurrence of maximum observed plasma concentration
TSH Thyroid -Stimulating Hormone
TSQM Treatment Satisfaction Questionnaire for Medication
UGT Uridine 5’-disphosphate glucuronosyltransferase
ULN Upper Limit of Normal
U/S Ultrasound
VAS Visual analog scale
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 15 12July2018VC Vital Capacity
VL Viral Load
vs. Versus
WBC White Blood Cell
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 16 12July20181. INTRODUCTION
1.1. Background
Sjogren’s S yndrome ( SjS) is estimated to affect approximately  1% of the population worldwide 
{Patel 2014}; it is a sy stemic autoimmune disease that is primarily  diagnosed in women [ADDRESS_1036013] often
, RA or SLE. Although prior convention was to label
these patients as “secondary ” SjS, the distinction is arbitrary  and the designations of “primary ” 
and “secondary ” have fallen out of favor {The Sjogren's Sy ndrome Foundation 2016 }.
The features of SjSinclude the classic s ymptoms of dry  eyes and dry  mouth, but also generalized 
fatigue with myalgias and arthralgias
. Man y patients with SjS also suffer from cognitive 
difficulties, and find it increasingl y difficult to perform their occupation . Due to the nonspecific 
nature of the disease, it is often undiagnosed or misdiagnosed . Therefore, patients remain 
generall y untreated, unless they have another autoimmune sy ndrome (eg, RA or SL E) for which 
they are receiving care. Immune dy sfunction and autoimmunity  are evident by  [CONTACT_756936] -associated antigens A and B (SSA and SSB), and the abnormal histology  of 
exocrine glands, with ectopic germinal center formation {Fox 2005}. Although the perception is 
that this disease is generally  benign, there may  be serious multiorgan consequences, including 
early cerebro -cardiovascular disease, pulmonary  and renal disease 
{Fox 2005}. An increased risk 
of lymphoma has also been demonstrated for patients with SjS{Fox 2005 }.
Therapeutic options for SjSare few. There are no approved disease -modifying ,anti-rheumatic 
drugs (DMARDs) for SjS, and 
only limited clinical trial data in SjSfor the various newer 
biologic and s ynthetic DMARDs a pproved for other indications. Milder 
SjSis often treated with 
oral and ocular h ydration, non- steroidal anti -inflammator y drugs (NSAIDs) , hydroxy chloroquine
(HCQ) and/or low dose oral steroids. Although treatment with methotrexate (MTX) and other 
conventional sy nthetic immunomodulators has been attempted, there are no strong data 
demonstrating amelioration of disease or its long-term effec ts.Thus, a need exists for new 
therapi[INVESTIGATOR_756915].
Filgotinib (GS -6034, formerly  GLPG0634) is a potent and selective oralinhibitor of JAK1 being 
developed b y [COMPANY_009] Sciences, Inc. ([COMPANY_009]) and Galapagos NV for the treatment of 
inflammatory  diseases .JAK1 is believed to play  an integral part in the pathogenesis of various 
autoimmune diseases, due to its role in inflammatory  cytokine signaling.
GS-[ADDRESS_1036014] ive oral inhibitor of BTK being 
developed by [CONTACT_756937] P hann aceutical Co, Ltd. (Ono) for the ti·eatme nt ofB-cell 
malig nanci es and inflammato1y diseases. BTK is an intracellu lar tyros ine kinase primarily 
expressed in hematopoietic cell lineages { Genevier 1994 }, { de Weers 1993 }, { Smith 1994 }, and 
mediates immu norecepto r sign aling in B lymp hocytes , anti gen-presenting cells , and mast cells , 
basoph ils, and osteoclasts . In addit ion, BTK is involved in integrin receptor and adapto r prote in 
signaling , through whic h it plays a role in cell adhes ion { de Rooij 2012 } and osteocl ast 
differentiation {Lee 2008}, {Shinohara 2008 }, {Tai 2012 }. 
Give n the i mpo rtant roles of these prote ins (JAKl , SYK, and BTK) in immune cell signaling , 
inhibitio n of these targets is expected to ameliorate autoimmune disease, via pleioti·op ic 
anti-inflammato1y effects . 
1.2. Filgotinib 
1.2.1. Nonclinical Pharmacolo gy and Toxicolo gy 
CON FIDENTIAL Page 17 12 Ju ly2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences, Inc. 
1.2.2. Clinical Trials of Filgotinib 
1.3. GS-98 76 
1.3.1. 
[IP_ADDRESS]. Nonclinical Pharmacology and Toxicology 
Nonclini cal Phaimacology and Safety Phaimacology 
CONFIDENTIAL Page 18 Final 
Amendment 1 
12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
[IP_ADDRESS]. Nonclinical Toxicology 
CONFIDENTIAL Page 19 Final 
Amendment 1 
12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
1.3.2. Clinical Trial s of GS-9876 
CONFIDENTIAL Page 20 Final 
Amendment 1 
12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
1.4. GS-4059 
1.4.1. Nonclinical Pharmacolo gy and Toxicolo gy 
CONF IDENTIAL Page 21 Final 
Amendment 1 
12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
CONF IDENTIAL Page 22 Final 
Amendment 1 
12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
1.4.2. Clinical Trials of GS-4059 
1.5. Rationale for Current Study Final 
Amendment 1 
Therapeutic options for SjS are few. There are no a ppro ved DMARDs for the ti·eatment of SjS, 
and there are o nly limit ed clinical ti·ial data in SjS us ing newer biologic and synthetic DMARD s 
appro ved for other indications. Milder SjS is o ften ti·eated with oral and ocular hy drati on, 
NSAID S, HCQ and/or low dose oral stero ids; highly active disease is ti·eated off-label with 
significant immun osuppr ession. A lthough u-eatment with MTX and other conventional synthetic 
immun omodulators has been attempted in SjS, there are no sti·ong data showing amelioration of 
the di sease or its sequelae. {Kruszka 2009 }, {Ramos-Casals 2005 }, {Mariette 2015}. For the chy 
eyes and chy mouth assoc iated with SjS (keratoco njunctivitis sicca and xerostomia), 
topi[INVESTIGATOR_756916] { Rising 
Phaimace uticals Inc}, {[COMPANY_007] 2014} are u sed for symptomatic conu-ol {Kruszka 2009 }, {Wu 
CONF IDENTIAL Page 23 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
CONFIDENTIAL Page 24 Final 
Amendment 1 
12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 25 12July20181.6. Rationale for Dose Selection
Filgotinib: Results from Phase 2a studies (GLPG 0634- CL-201 and GLPG 0634- CL-202) and 
Phase 2b studies (GL PG0634 -CL-203 and GLPG 0634 -CL-204) showed that 200 mgonce dail y 
filgotinib was well tolerated and demonstrated clinical efficacy  (ACR20/50/70 and 
DAS28[CRP]) in subjects with RA. Exposure -response anal ysis ofdata from Phase 2 studies 
indicated a dose -dependent increase in efficacy , with a plateau at the 200 mgtotal dail y dose on 
the dose -
response curve. These results are consistent with the relationship observed between 
filgotinib exposures and pSTAT1 activation (ex -vivo) following single and multiple filgotinib 
doses, where maximal inhibition of pSTAT1 (~78%) was achieved at or above the 200 mgtotal 
daily  dose { Namour 2015}. Filgotinib [ADDRESS_1036015] th e potential to be efficacious in SjS.
GS-
9876: In the multiple ascending dose (MAD) study  (GS-US- 379-1900), doses of up to [ADDRESS_1036016] the potential to show clinical 
activity inSjS.
GS-4059: A dose of 40 mgonce dail y GS- 4059 was selected for this study based on available 
PK, PD, and safet y data, guided b y the goal of maximizing target occupancy. Based on a PK/PD 
analysis from two Phase 1 studies in healthy  volunteers and subjects with RA (GS -US-401-1765 
and GS -US-
407-1833), a dose of 40 mgonce daily  GS- 4059 is expected to provide near maximal 
BTK occupancy  over the dosing interval (median >90% occupancy ). In addition, t he selection of 
40mgonce dail y GS-4059 for this study  is supported by  [CONTACT_756938] y and 
tolerability  profile of GS -4059. Preliminary  results from Study  GS-US- 407-1833 demonstrate 
that a total daily  dose of 20 mgGS-4059 was well tolerated during a 4 -week treatment period in 
subjec ts with RA ( N=21 ). The maximum tolerated dose (MTD) of GS- 4059 was 480 mgonce 
daily  in subjects with non- Hodgkin’s ly mphoma ,with dose limiting toxicity events of rash and 
non-immune reaction at the 600 mgonce dail y dose; no MTD was identified in subjects with 
chronic l ymphocy tic leukemia at doses up to [ADDRESS_1036017] the potential to show clinical activity  in 
subjects with SjS .
1.7. Risk/Benefit Assessment for the Study
Sjogren’s Syndrome is a chronic, s ystemic inflammatory
 disease that affects approximately  
1%of the populatio n. Currentl y , there are no DMARDs approved for the treatment of SjS . 
Theneed for new , therapeutic options with a favorable efficacy  and safet y profile hasprompted 
efforts to evaluate orally  administered, small molecules in this disease setting .
Please refer to respective I nvestigator’s Brochure s(IB) for updated safet y information and 
risk/benefit assessment.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 26 12July2018Filgotinib, a once -daily,oral, and potent JAK -1inhibitor, is being developed for the treatment of 
RAand other autoimmune diseases .In the ongoing and concluded studies, filgotinib has been 
generall y safe and well tolerated The primar y endpoint was achieved in two large dose ranging 
studies (GL PG-CL-203 and GL PG-CL-204) evaluating the effect of filgotinib on RA disease 
activity . However, a potential increased risk of infection may  be considered consistent with the 
mechanism of JAK inhi bition. I n the filgotinib RA program, deaths 
were reported due to 
infectious etiologies. 
Nonclinical studies in rats and dogs identified l ymphoid tissues and testes as target organs for 
filgotinib; microscopic findings in the testes included germ cell dep letion and degeneration in 
both species , with reduced sperm content and reduc edfertility  in male rats. Theclinical 
relevance of nonclinical testicular findings in rats and dogs is unknown. Amale safet y stud y is
ongoing to assess the effect s, if an y,of filgotinib on semen parameters in males with 
inflammatory  diseases . Until the definite results of this study  are available, all males will be 
informed about this potential toxicit y in the informed consent form andonly men 
understanding 
and accepting the p otential risk for loss of fertility will be enrolled. In addition SjS is a disease of 
female predominance and depending on the study population the incidence of SjS in females is 
reported to be 10 to 20 fold higher in females than males {Patel 2014}.
GS-[ADDRESS_1036018] therapeutic value in the treatment of 
allergic and autoimmune diseases. Clinical trials with fostamatinib (an experimental SYK 
inhibitor) have demonstrated responses in RA and in 
idiopathic thrombocy topenic purpura .
In non-clinical studies of GS -9876 in rats and in cynomolgus monkey s, the primary  observe d 
effects were reversible, dose- dependent decreases in circulating l ymphocy tes and ly mphocy tes in 
various tissues (spleen, lymph nodes, thy mus, and/or bone marrow), consistent with the expected 
pharmacology of SYK inhibition {Barr 2012 }. Additionally , effects on ery throcy te turnover were 
seen in rats, and effects on hemostasis (hemorrhage and thrombosis) were seen in monkey s. In 
the ongoing and concluded clinical studies, GS- [ADDRESS_1036019] diverse biological functions, from cellular proliferation, 
differentiation and adhesion to innate and adaptive immune responses. As such, pharmacological 
inhibitors of BTK are being activel y pursued as potential immunomodulatory agents for the 
treatment of autoimmune and inflammatory
 disorders.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 27 12July2018Innon-clinical studies of GS-4059 in rats and in monkey s,the primary  effects were generall y 
minor, reversible, dose -dependent decreases in l ymphocytes in various tissues (spleen, l ymph 
nodes, and/or th ymus) consistent with expected pharmacologic effects of BTK inhibition. 
Additionally , minor, reversible effects on ery throcy tes were seen in rats and monkey s. Effects on 
the pancreas, adrenal and thy roid glands, liver and kidney  in rats were considered to be 
species -specific and of limited to no relevance to humans. I nclinical studies of GS-[ADDRESS_1036020] been administered to patients with 
hematologic malignancies with an acceptable safety  profile for the population studied .
Based on available non -clinical findings, GS -9876 is not contraindicated in pregnancy , although 
pregnancy  in GS -9876 trials should be avoided. However, f ilgotinib and GS- 4059 are 
contraindicated in pregnancy ; highl y effective contraception is to be used across all clinical 
studies to mitigate this risk. Measures to minimize other potential risks to subjects will include 
site/investigator training regarding monitoring for infection, and collection of AEs of special 
interest, including major adverse cardiac events, malignancies, infections, and specific laboratory  
abnormalities.
Preclinical and clinical data forfilgotinib ,GS-[ADDRESS_1036021] an acceptable level of risk that is consistent with that of other 
immunomodulat ory agentsin patient population swith autoimmune diseases . Given the clinical
and nonclinical data available to date for these 3 drugs
, and their overall safety , tolerability , and 
PK characteristics, there is a favorable benefit: risk profile for development of these agents in 
SjS. This study  will help to determine the potential of filgotinib , GS-9876, or GS- 4059 as much 
needed alternative sto existing treatment option s for SjSand related diseases.
1.8. Compliance
This study  will be conducted in compliance with th is protocol, GCP, and all applicable 
regulatory  requirements.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 28 12July20182. OBJECTIVES AND ENDPOINTS
Study Objectives Study Endpoints
Primary objective:
To assess the efficacy of filgotinib , GS-9876, and 
GS-4059 in adult subjects with active SjSPrimary endpoint :
The primary endpoint is the proportion of subjects 
fulfilling protocol -specified response criteria at 
Week
12, as compared to baseline.
Response is defined as follows:
For subjects w ith elevated hsCRP (defined as ≥ 1.5 
upper limit of normal (ULN) of hsCRP ) at Day 1, 
subjects are considered to be a responder if they 
achieve all of the following :
-≥ 20% improvement in hsCRP
- ≥ 20% improvement in at least [ADDRESS_1036022] reported, SjS related visual analog 
scales (VAS; subject’s assessment of global 
disease , pain, oral dryness, ocular dryness and 
fatigue)
-no w orsening (defined as > 30mm increase 
from baseline) in any of the above VAS
For subjects w ithout elevated hsCRP (< 1.[ADDRESS_1036023] of 
hsCRP) at Day 1, subjects are considered to be a 
responder if achieve all o f the following:
-no increase ≥ 1.[ADDRESS_1036024] of hsCRP
- ≥ 20% improvement in at least [ADDRESS_1036025] reported, SjS related VAS (subject’s 
assessment of global disease, pain, oral 
dryness, ocular dryness and fatigue)
-no w orsening (defined as > 30mm increase 
from baseline) in any of the above VAS
Secondary objectives:
To assess the safety and tolerability of filgotinib, 
GS-9876 ,and GS-4059 in adult subjects with active 
SjS
To assess the effect of filgotinib, GS -9876, and GS-
4059 on patient reported outcomes in 
active SjS, 
including fatigue, disability ,and quality of lifeSecondary endpoints:
Change from baseline in ESSDAI and ESSPRI at 
Weeks 12 and 24.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 29 12July2018Study Objectives Study Endpoints
The exploratory objectives of this study are: The exploratory endpoints of this study are:
CCI
CCI
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445-4189 
[COMPANY_009] Science s, Inc. 
3. STUDY DESIGN 
3.1. Study Design Final 
Amendment 1 
Adult male and female subjects who provide written, info1med consent will enter a Screening 
period (28 days) during which they will be evaluated for eligibil ity, based on the 
Inclusion/Exclusion criteria. 
At Day 1, eligible subjects will be randomized to study dmg (see Section 3.2). Subjects will 
return to the study site for scheduled study visits at Weeks 2, 4, 8, 12, 18, 24, 26, 28, 32, 36, 42 
and 48. After completion of the Week 24 assessments and procedures, subjects on placebo will 
be re-randomized 1: 1: 1 to filgotinib , or GS-987 6, or GS-4059, in a blinded fashion. Dosing will 
continue through Week 48. 
Subjects who discontinue study drng for any reason ( other than noncompliance) may continue to 
pa1iicipate in schedu led study visits and procedures , as long as deemed medically appropr iate by 
[CONTACT_093]. Subject s who discontinue all study participation will have an early te1mination 
(ET) visit; these subjects , and those who complete the study , shou ld return to the study site for a 
follow-up visit, [ADDRESS_1036026] dose of study dmg (subjects who have discontinued study 
dmg 4 weeks prior to the ET/Week 48 visit, do not need a follow up visit). 
Figure 3-1. 
Scree ning 
28 days Study Design Schematic 
Dayl 
Placebo Week24 
Filgotioib 
200mgQ D 
GS-9876 
30mgQD 
GS-4059 
40 mgQD 
Filgotinib 200 mg QD 
GS-9876 30 mg QD 
GS-4059 40 mg QD 
For details regarding dosing and blinding , see Section 5.7. Week48 
FU visit 
4week.5 
aft.et· last 
dose of 
stud y 
drug 
For details regarding concomitant and excluded medications , see Section 5.8. 
For study visit schedule and procedures, including clinical laborato1y tests and 
see Schedule of Activities in Section 6 and Appendix 2. 
CONFIDENTIAL Page 30 12 July 2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
3.2. Study Treatment s Final 
Amendmen t 1 
Following comple tion of screening assess men ts, eligible subjects will be randomized 1: 1: 1: [ADDRESS_1036027] or PTM: 
• Filgotinib 200 mg arm (n=35 ): filgotinib (1 x 200 mg tablet once daily) + PTM GS-9876 
(1 x tablet once daily) + PTM GS-4059 (1 x tablet once daily) 
• GS-9876 30 mg arm (n=35 ): PTM filgotinib (1 x tablet once daily)+ GS-9876 (1 x 30 mg 
tablet once daily) + PTM GS-4059 (1 x tablets once daily) 
• GS-4059 40 mg arm (n=35 ): PTM filgotinib (1 x tablet once daily)+ PTM GS-9876 
(1 x tablet once daily) + GS-4059 (1 x 40 mg tablet once daily) 
• Placebo arm (n=35): PTM filgotinib (1 x tablet once daily)+ PTM GS-9876 (1 x tablet 
once daily) + PTM GS-4059 (1 x tablet once daily) 
Randomizat ion wi ll be stratified by [CONTACT_756939]1 y d rngs at baseline 
(YIN: csDMARDs or corticostero ids), and the hematolog ic + biol ogical component scores of the 
ESS DAI obtained at screening (combined score of <2 or ~ 2). 
3.3. Duration of Treatment 
Subjects will be dosed for up to [ADDRESS_1036028] visit (Wee k 48 or ET); the Fo llow-Up Visit will not be perfonned if the subject has 
discontinued study drng [ADDRESS_1036029] disco ntinues study dosing (for example , as a result of an AE), eve1y attempt should 
be made to keep the su bject in the study an d continue to perfon n the r equired study -related 
follow-up an d proced mes. If this is not possible or acceptable to the subject or investigator , 
th e su bject may be withdrawn from the study . In these cases , an Early Term ination visit shou ld 
be perfonned as soon as possible. 
CONFIDENTIAL Page 31 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 32 12July20183.4.1. Study Drug Interruption Consideration s
The Medical Monitor should be consulted prior to study
 drug interr uption when medicall y 
feasible.
Study  drug interruption should be considered in the following circumstances; prior to resumption 
of study  drug, the investigator should discuss the case with the [COMPANY_009] medical monitor:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical st atus to a significant degree.
Subject is scheduled for emergency  surgery  (excluding minor skin procedures under local or 
no anesthesia); timing of study  drug pausing should be determined in consultation with the 
[COMPANY_009] medical monitor .
If the subject has an y signs or symptoms suggestive of infection (regardless of severit y), 
study  drug dosing should be immediately
 interrupted, and the medical monitor notified. 
Any subject who develops a new infection during the study  should undergo prompt and 
complete diagnostic testing appropriate for an immunocompr omised individual, and the 
subject should be closel y monitored. Study  treatment should not be resumed until the 
subject’s event has resolved, pe r judgment of the investigator.
NOTE: During the time of study  drug interruption for an y of the above, the subje ct may  continue 
to have study  visits and to take part in procedures and assessments, if deemed medicall y 
appropriate b y the investigator.
3.4.2. Study Drug 
Discontinuation Considerations
The Medical Monitor should be consulted prior to study  drug discontinuation whenever feasible.
Study  medication should be permanently  discontinued in the following instances:
Any opportunistic infection
Any serious infection that requires antimicrobial therap y or hospi[INVESTIGATOR_059], or any infection 
that meets SAE reporting criteria.
Complicated herpes zoster infection (with multi
-dermatomal, disseminated, ophthalmic, 
orCNS involvement)
Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
subject’s ability  to continue study -specific procedures or is not considered to be in the 
subject ’s best interest
Need for prohibited concomitant medication (see Section 5.8)
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 33 12July2018Subject request to discontinue for an y reason
Subject noncompliance, as per judgment of investigator
Request from [COMPANY_009], a regulatory  agency  or an IRB or IEC
Female subject becomes pregnant during the study ; refer to Section [IP_ADDRESS]
Positive HCV VL
Investigator discretion
Laboratory  criteria:
After becoming aware of any  of the below described abnormal laboratory  values at any  time, 
anunscheduled visit should occur within [ADDRESS_1036030] 
should be directed per the investigator
.
total white blood cell (WBC )count < 2000 cells/mm3(SI: <2.0x109cells/L)
neutrophil count < 1000 neutrophils/mm3(SI: <1.0x109cells/L)
hemoglobin < 8.0g/dL (SI : <80g/L)
platelet count < 75,000 platelets/mm3(SI: <75.0x109cells/L)
AST or ALT elevation:
■> 3xUL N with at least 1 total bilirubin value >2xULN
■ > 3xUL N with elevated international normalized ratio (INR)
■ > 5xUL N, regardless of total bilirubin or accompany ing s ymptoms
Note : For the above described AST or ALT elevations , additional investigations ( such as:
review of ethanol, recreational drug use, dietary  supplement consumption; testing for 
acute hepatitis A, B or C infection and biliary  tract imaging )should be promptly
considered b y the investigator; these subjects should be discussed with the study
 Medical 
Monitor .
estimated creatinine clearance < 40 mL/min based on the Cockroft -Gault formula
Filgotinib , GS-9876 and GS-4059 
Protoco l GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
Subjects who stop study chugs for any r eason will not be replaced . Subjects with drawing from 
the study shou ld complete the ET and 4 week Follow Up visits, as applicable. Subjects may 
withch·aw from the study at any time without providing reaso n(s) for with ch·awa l and without 
prejudice to fmther ti·eatme nt. The r eason(s) for withch·awal will be documented in the somce 
documents and in the electi·onic case repo1i f01m (eCRF) . 
Reaso nable efforts will be made to contact [CONTACT_63381] -up. All contacts and 
contact [CONTACT_756940]'s file. 
3.5. End of Study 
The end of study is defined as when the last subject has completed their final study visit 
(Week 48 or ET) plus the [ADDRESS_1036031] ti·eatme nt visit (Follow -Up Visit - if applicab le). 
3.6. Post Study Care 
The long tenn care of subjects will rema in the respo nsibility of their prima 1 y ti·eating physician . 
3.7. Bio mark er Testing 
CONFIDENTIAL Page [ADDRESS_1036032] of Exploratory Biomarker Samples
3.7.1. Biomarker Samples to Address the Study Objectives
:
The following biologic specimens will be collected in this study  in order to evaluat e the 
association of exploratory  systemic and/or tissue specific biomarkers with study  drug response, 
including efficacy  and/or adverse events, and to increase knowledge and understanding of SjS
and related diseases, the development of a companion diagnostic, and/or to help inform how 
inhibition of JAK1, SYK, or BTK affect downstream markers. B ecause biomarker science is a 
rapi[INVESTIGATOR_204935], it is not possible to specify  prospectively  all tests that will 
be done on the specimens provided. The testing proposed in Table 3-1based upon the current
state of scientific knowledge. It may be modified during or after the end of the study  to remove 
tests and/or to add new tests based upon the growing state of knowledge .The biomarker sample 
collection schedule is described in the Schedule of Assessments Table (Appendix 2).
CCI
Filgotin ib, GS-[ADDRESS_1036033]’s 
previous results; due either to error (eg, a mishandled/hemoly zed sample), or to an extenuating 
circums tance which has since resolved.
1) M ale or female 18 to 75 yearsof age (inclusive) at the time of signing initial consent, 
with all of the following at Screening:
a.Diagnosis of SjSbased on AECG classification (Appendix 7)
b.Active 
SjS, with ESSDAI ≥5
c.Seropositivity  for anti- SSA or anti- SSB, per central lab oratory
2) A negative serum pregnancy  test at Screening and a negative urine pregnancy  test at 
Day 1arerequired for female subjects of child
-bearing potential (as defined in
Appendix 5)
3)
Starting at the time of written consent, through the study , and for 90 days (male) 
and36days (female) following the irlast dose of study  drug :
a.Male and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as 
described in Appendix 5,
b.Male subject s must agree to refrain from sperm d onation
c.Female subjects must agree not to breastfeed or to donate/harvest eggs for the 
purpose of fertilization ,
4)
Subjects with prior exposure to a B- cell depleting bDMARD (at an y time) must have a 
documented return of CD19+ B cell s at Screening.
5) Stable dose (defined as no change in prescription for at least 4 weeks prior to Day 1) of
NSAIDs, HCQ, MTX and/or oral corticosteroid s
is permitted during the study , but not 
required (see protocol Section 5.8for definition s, full list of allowed prior and 
concomitant medications and permitted doses) .
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 38 12July20186)Meet one of the following (a or b) tuberculosis (TB) Screening crite ria:
a.No evidence of active or latent TB:
Negative history  of TB infection and
Negative QuantiFERON® TB -Gold In-Tube test and
Note: QuantiFERON® tests with inconclusive results may  be repeated one time. 
Ifthe repeat result is also inconclusive, the subject is excluded from the study .
Negative chest X -ray results ( radiographs taken at Screening or within 
90days prior to Screening with films or report available for investigator 
review).
b.Subjects with prior latent TB who have been treated with a full course of 
proph ylaxis as per local g uidelines.
Note: Appropriate documentation 
of previous treatment is required.
In these cases, a QuantiFERON® TB- Gold In- Tube test is not needed, but a chest 
radiograph must be obtained within 3 month s prior to Screening (report or films 
must be available).
In addition, these cases must be approved b y the Medical Monitor prior to 
enrollment.
Subjects with a new diagnosis of latent TB or prior untreated/partially  treated 
latent TB are NOT allowed ( ie, subjects who require prophy lactic therap y for TB 
during th e stud y). Subjects with any  prior active TB are excluded regardless of 
treatment.
7)Are willing and able to sign the informed consent form and compl y with study 
requirements, procedures, and scheduled visits
.
Note: Subjects who cannot read or understand the ICF may  not be enrolled by  a guardian, 
representative, or an y other individual
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria must not be enrolled in this study .
1) Conc urrent treatment at Screening with an y bDMARD ( prior bDMARD treatment 
allowed with appropriate washout as defined in Section 5.8)
2)Any prior use of cy clophosphamide
3)Use of cyclosporine within [ADDRESS_1036034] dose of study  drug (Day 1) or 
anticipated chronic use while on study  (other than o phthalmic cy clospori neas described 
as per Section 5.8)
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 39 12July20184)Clinically  significant abnormalities on 12-lead ECG as judged b y the investigator .
5)
Treatment with moderate or strong CYP3A induc ersor inhibitors within [ADDRESS_1036035] dose of study  drug (Day 1)or 
anticipated chronic use while on study  (seeSection 5.8)
6)Participation in any  clinical study  of an investigational drug within 4 week s or 5 drug 
half-lives prior to Screening, whichever is longer. 
Washout duration for e xposure to 
investigational b iologics should be discussed with the sponsor
7) T reatment with any commerciall y available or investigational drug listed below within 
3month s of Screening:
a.BTK inhibitor, such a s ibrutinib , or
b.SYK inhibitor ,such as fostamatinib , or
c.JAK inhibitor, such as t ofacitinib or baricitinib
8)History  of opportunistic infection or immunodeficiency  syndrome which would put the
subject at risk, as per investigator judgment
9)History  of symptomatic H erpes zoster or Herpes simplex infection within 12 week s prior 
to Screening or history  of disseminated/complicated Herpes zoster infection 
(multi -dermatomal involvement, ophthalmic zoster, CNS involvement or postherpetic 
neuralgia) at an y time
10)
Known hy persensitivity  to the study  drug , itsmetabo lites, or any  of the excipi[INVESTIGATOR_841] s ,
orprevious clinicall y significant allergic reaction to any  drug, per judgment of the 
investigator
11) A nother highly  active inflammatory /autoimmune/rheumatic disease (such as highl y 
active RA , highl y active SLE, highly active nephritis or CNS inflammation) which would 
compromise subject safety or interfere with the conduct of the study .
Note: Subjects with stable autoimmune disease, (eg, RA, SL E, or thy roiditis) not requiring 
prohibited medications are permitted
12) H istory  of head/neck irradiation, sarcoidosis, graft v host disease, or IgG4related disease
{Stone 2012}, {Umehara 2012}
13)
Female subjects who are pregnant, breastfeeding, or planning to become pregnant or 
breastfeed during the study  up to [ADDRESS_1036036] dose of study 
drug (as per Appendix 5)
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 40 12July201814)Major surgery  (requiring r egional block or general anesthesia) within 30 days prior to 
Screening, or planned during the stud y
15)History  of live or a ttenuated vaccines within 30days of Day 1, or planned during the 
study period or for [ADDRESS_1036037]'s last dose of study  drug . Refer to 
Section 5.9
16)History  of malignancy  within the past 5 y ears prior to Screening (except for adeq uatel y 
treated 
basal cell carcinoma or non- metastatic squamous cell carcinoma of the skin or 
cervical carcinoma in situ, with no evidence of recurrence ). 
17)Positive serology  for human immunodeficiency  virus (HIV) 1 or 2 at Screening ,
18)Hepatitis B virus ( HBV )surface antigen (HBsAg) or positive HBV core antibodies at 
Screening
19)Hepatitis C virus ( HCV )antibodies and positive HCV RNA viral load ( VL).
Note: Subjects with positive HCV Ab, but negative HCV RNA VL are eligible per 
investigator judgment, but require monitoring as outlined in Appendix 2.
Subject with active HCV during the stud yas evidenced b y RNA positivity  will be 
discontinued from study  drug as outlined in Section 3.4.
20)
Serious active infection of an y kind at Screening or Day 1
21)Blood loss (> 500 mL) orblood product transfusion within 12 week s of Day 1
22)Known bleeding disorder or hypercoagulable state; antiphospholipid antibody  syndrome 
with prior clinically  significant event (per judgment of investigator); or on chronic 
anticoagulation or anti -platelet therap y
Note: A spi[INVESTIGATOR_505825] y ≤325 mg/day for cardiovascular prophy laxis is permitted
23)Current drug or alcohol abuse, or heav y tobacco use, as per judgment of investigator
24)Clinically  significant laboratory  values at Screening, including the following :
a.Hemoglobin < 9g/dL (International Sy stem of Units [SI ]: <90g/L)
b.Neutrophil count <1.5 x 109/L(SI: <1.5 x 109cells/L)
c.Platelets <100 x 103cells/mm3 (SI : <100 x 109cells/L );
d.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5x upper 
limit of normal (ULN)
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 41 12July2018e.Total bilirubin level ≥2x ULN unless the subject has been diagnosed with 
Gilbert’s disease and this is clearl y documented
f.Estimated creatinine clearance <60mL/min per Cockcroft -Gault 
equation
Note: Abnormal values may  be rechecked one time, at discretion of the investigator if 
an error is suspected
4.4. Screen Failure
Subjects who do not meet the I nclusion/Exclusion criteria for entry  into the study  
(“screen failures”) may  be rescreened one time in selected cases with written permission from 
the Sponsor; for example, to meet a drug washout period.
Subjects who do not enter the study due to administrative reasons (for example, exceeding the 
screening window due to issues with appointment scheduling or obtaining results of laboratory  
data) may  be rescre ened one time with written permission from the Sponsor; this rescreening 
option is in addition to the rescreening permitted above.
Neither of the rescreening options is to be used to recheck a subject who is likely  unsuitable for 
the study , for example, to check whether their chronically  abnormal laboratory  test is closer to 
normal range .
Subjects who are permitted to rescreen must repeat the informed consent process and sign a new 
consent form; they  will receive a new subject number. In these cases, labscreening tests do not 
need to be repeated if they  were performed within 28days of randomization, and within 90 days 
forQuantiferon and/or Chest X -ray, if needed .
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
5. INVESTIGATIO N AL MEDICI NAL PRODUCTS 
5.1. Randomization , Blinding and Treatment Code s Final 
Amendment 1 
An Interactive Web and Mobile Respo nse Syste m (IWRS) will be empl oyed to manage subject 
randomization and ti·eatment assignm ents. It is the r espo nsibility of the investigator to ens ure that 
the s ubject is eligible for the s tudy prior to em ollment. Subjects will be assigned a Screening 
numb er at the time of consent. 
5.1.1. Procedure s for Breaking Treatment Codes 
In the event of a m edical emer gency where breaking the b lind is re quired to prov ide medical care 
to the su bject, the investigator m ay obtain the individual subject ti·eatment assignm ent d irectly 
from the IWRS system. [COMPANY_009] recommends, but does not require, that the investigator contact 
[CONTACT_756941] l Mon itor before breaking the b lind. Treatment assignm ents should rema in 
blinde d unless that knowledge is necess aiy to detennin e emer gency medical cai· e for the subj ect. 
The rationale for unblinding must be clearly explained in source documentation and on the 
elecu-onic case repo1 i fonn (eCRF), along w ith the date on w hich the ti·eatment assignme nt was 
unblinded. The investigator is re quested to contact [CONTACT_941] G ilead Medical Monitor promptly in case 
of any ti·eatment unblinding. 
Blinding of s tudy ti·eatment is critical to th e integrity of this Phase 2 clinical ti·ial and ther efore, 
if a subject's u-eatment assignment is dis closed to th e investigator, the s ubject will be 
discontinued from the u-ial. 
[COMPANY_009] Phaimacov igilance and Epi[INVESTIGATOR_623] (PVE) may independently unblind cases for 
expedited repo1 iing of susp ected unexpected serious adve rse reactions (S[LOCATION_003]Rs) to Regulato1 y 
Authorities. 
5.2. Description of Filgotinib and PTM Filgotinib 
CONFIDENTIAL Page42 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
5.3. Description of GS-9876 and PTM GS-9876 
5.4. Description of GS-4059 and PTM GS-4059 
5.5. Packaging and Labeling of All Study Drugs for this Protocol Final 
Amendment 1 
Filgotin ib 200 mg tablets , PTM filgotinib 200 mg tablet s, GS-9876 30 mg tablet s, PTM GS-9876 
30 mg tablet s, GS-4059 40 mg tablet s, and PTM GS-4059 40 mg tablet s for each drng are 
packaged in white, high density polyethylene (HDP E) bottles. Each bottle contains 30 tablets , 
silica gel desiccant and polyester packing material. Each bottle is en close d with a w hite, 
continuous thread, child-resista nt polypro pylene screw cap with an induction-sealed and 
aluminum-fa ced liner. 
All study chug ( s) to be disti·ibuted to cente rs in the US and other paiiicipat ing counti ·ies shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drng Admini su-ation 
(FDA), the E uropean Union (EU) Guideline to Good Manufacturing Practice-Annex 13 
(Investigatio nal Medic inal Product s), and/or other local regulation s, as applicable. 
CONFIDENTIAL Page43 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 44 12July20185.6. Storage and Handling of Study Drugs
Study  drugs (filgotinib, GS -9876, GS - 4059, and PTM tablet sfor each )should be stored at 
controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C 
(59°F and 86°F). Storage conditions are specified on the label. Until dispensed to the subjects, 
allbottles of study  drugs should be stored in 
a securely  locked area, accessible onl y to authorized 
site personnel.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the contain er in which they  were supplied.
Consideration should be given t o handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye con tact or exposure when handling.
5.7. Dosage and Administration of Investigational Medicinal Produc ts
Subjects will receive study  drugs according to their randomization arm as described in 
Section 3.2.
The study  drugs should be administered orally  once daily  with water, with or without food. 
Thestudy  drugs should be swallowed whole and all 3 tablets administered at the same time . 
Subjects 
should be instructed to take stud y drug sat approximately  the same time each morni ng.
On study  visit day s, subjects should not take their study  drugs at home, but should bring them to 
the clinic and take them asinstructed b y site staff (in order to enable timing of PK blood draws 
and/or other procedures) .
On Day 1, subjects will be instructed to take their dose in clinic as t he last in- clinic study  
procedure (after all other procedures for t hat visit have been completed).
AtWeeks 4, 8, 12, 24, 36 and 48/ET, subjects will be instructed to take their dose after 
PKassessments have been completed .
At Week 18, subjects will be instructed to take their dose in clinic in order to have a pre- dose 
biomarker blood draw , and a post -dose PK and biomarker blood draw approximately  [ADDRESS_1036038] should be instructed to return the missed 
unused tablets to the study  drug bottle sand take the next dose at the regularly  scheduled time. 
Subjects should be reminded never to double the missed dose of study  drug with their next dose, 
under an y circumstances.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 45 12July20185.8. Prior and Concomitant Medications
Prior medications that are allowed in this study :
See I /E criteria
Prior medications that are prohibited in this study :
See I /E criteria
Concomitant medications allowed in this study :
Doses of concomitant chronic medications should be stable ( defined as no change in 
prescription for at least 28daysprior to Day 1) and should be continued at the stable dose 
throughout at least thefirst 12 week
sof the study.However, dose adjustment sfor toxicities 
are allowed , and should be recorded in the eCRF, along with documentation of the AE 
requiring the dose change.
Cevil imine or pi[INVESTIGATOR_1227] ,as prescribed b y investigator.
Ophthalmic cy closporine, as prescribed b y investigator.
Oral NSAIDs, as prescribed by  [CONTACT_1697].
Oral or injectable MTX ≤ 20mgperweek (subjects on MTX should also be on chronic 
folic acid supplementation [or equivalent], as per local standard of care).
All local standard ofcare practices for the administration of MTX, including laboratory  
testing, follow -up care, and contraindications should be performed throughout the study . 
The concomitant use of medicines which may  increase the risk of hepatotoxicity  and/or 
nephrotoxicity  with MTX (such as NSAIDs, salicy lates, leflunomide, or other folate 
antagonists) should be avoided, as much as po ssible, in accordance with clinical practice .
Chloroquine ≤ 250 mg/day or HCQ ≤ 400mg/day.
Oral leflunomide ≤ 20 mg/day (Leflunomide in combination with MTX is not allowed)
Azathioprine up to maximum of 2 mg/kg or 300 mg, whichever is lower
Vitamins, mine rals, or herbal supplements, as per judgment of the investigator.
Note : after completion of the Week 12 visit, the dose of an y of the above medications 
may be reduced, and subsequently  increased, as often as needed, per judgment of the 
investigator; however, the highest dose prescribed should not exceed the subject’s 
Baseline dose. Subjects requiring a dose higher than their Baseline dose for more than 
14consecutive day s should be withdrawn from study  drug, but may  continue with study  
visits.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 46 12July2018Oral c orticosteroids ≤ 10 mgprednisone (or equivalent) per day .
Note : after completion of the Week 12 visit, the dose of corticosteroids may be reduced ,
and subsequentl y increased , as often as needed, per investigator judgment ;however, the 
dose should not exce ed the subject’s Baseline dose. Subjects requiring oral 
corticosteroids > 10 mgprednisone /day should be withdrawn from study  drug, but may  
continue with study  visits.
Other chronic therapi[INVESTIGATOR_756917] (eg, antih ypertensives, female hormone
replaceme nttherap y, thyroid replacement therap y, anti -
depressants), asper judgment of 
the investigator .
Concomitant medications that are not allowed in this study :
Cyclophosphamide
Cyclosporine (other than ophthalmic cy closporine ,as described above)
Moderate or strong CYP3A inhibitors or inducers are prohibited within 2week s prior to 
the first dose of stud y drug and throughout the study .Strong P -gp inducers are prohibited 
within 3week s prior to 
the first dose of study  drug and throughout the study .
Examples of these medicines are provided below .
This list does not include medications such as anti -HIV agents that would be contraindicated 
based on other exclusion criteria (questions regarding these medications should be discussed 
with the Medical Monitor):
Drug C lass Agents Disallo wed
Strong CYP3A Inhibitorsaclarithromycin, conivaptan, itraconazole, ketoconazole, nefazodone, posaconazole, 
telithromycin, voriconazole, telaprevir, boceprevir, grapefruit juice, idelalisib ,
Viekira Pak ( ombitasvir, pari taprevir , ritonavir, d asabuvir ), troleandomycin , 
mibefradil
Strong CYP3A Inducersa, bCarbamazepi[INVESTIGATOR_050], phenytoin, rifampin, fosphenytoin, pentobarbital, primidone, 
rifabutin, rifapentine, phenobarbital, mitotane, avasimibe, St. John’s Wort , 
enzalutamide
Strong P -gp inducerscPhenobarbital, phenytoin, carbamazepi[INVESTIGATOR_050] , rifabutin, rifapentine, rifampin , St. 
John’s w ort,danshen (salvia miltiorrhiza)
Moderate CYP3A Inhibitorsa,fluconazole, erythromycin, diltiazem, dronedarone, aprepi[INVESTIGATOR_053], casopi[INVESTIGATOR_053], imatinib , 
verapamil, tofisopam, ciprofloxacin, cimetidine, cyclosporine, Schisandra 
sphenanthera, crizotinib , netupi[INVESTIGATOR_053], nilotinib , isavuconazole
Moderate CYP3A Inducersabosentan, thioridazine, nafcillin, modafinil, semagacestat, genistein
aIn vitro data indicated GS-9876 is a substrate of CYP3A4. Co -administration of CYP3A inhibitors may increase GS -9876 
exposure and coadministration of CYP3A inducers may decrease GS-9876 exposure.
bGS-4059 is a substrate of CYP3A and P -gp. Coadministratio n of strong CYP3A/P -gp inducers may decrease GS-4059
exposure.
cFilgotinib is a P -gp substrate. Coadministration of strong P -gp inducers may decrease filgotinib exposure.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 47 12July2018GS-[ADDRESS_1036039] the plasma concentration s of 
its substrates. Caution should be exercised when co- administering medicines that are
P-gp substrates with narrow therapeutic windows , such as digoxin, dabigatran etex ilate, 
ranolazine and aliskiren
The following medications are prohibited within [ADDRESS_1036040] dose of study  
drug and throughout the study :gold salts, 
minocycline, penicilamine, sulfasalazine, 
tacrolimus, sirolimus, everolimus, my cophenolate mofetil, etanercept, adalimumab, 
anakinra, or biosimilar versions of these drugs, wher e applicable
The following medications are prohibited within [ADDRESS_1036041] dose of study  
drug and throughout the study : infliximab, golimumab, certolizumab pegol, abatacept, 
tocilizumab, or biosimilar versions of these drugs, where applicable
Parenteral corticosteroids are prohibited during the first 24 week s of the study  (except for 
one joint injection, at a maximum dose of 40 mgtriamcinolone, or equivalent ; the injected
joint should be marked as “non
-assessible” for the remainder of the stu dy
Concurrent therap y with any anti -coagulant (eg, coumadin [warfarin], any  Vitamin K 
antagonist, any novel oral anticoagulant, heparin s or low molecular heparins, any  
inhibitors of factor Xa) or any  anti-platelet therapy  (eg, adenosine diphosphate [ADP] 
r
eceptor inhibitors, phosphodiesterase inhibitors, Protease -activated receptor 1 ( PAR -1)
antagonists, Gly coprotein 2b/3a inhibitors) . NOTE: aspi[INVESTIGATOR_505825] y ≤ 325mg/day for 
cardiac proph ylaxis is allowed.
5.9. Vaccine Guidelines
Prior to study  participation, it is recommended that the subject’s vaccinations be brought up 
to date according to local vaccination standards , as much as possible .
Live or attenuated vaccines (including, but not limited to, varicella and inhaled flu vaccine) 
are prohibited within 30daysof Day 1, throughout the study , and for [ADDRESS_1036042] 
dose of study  drug.
Subjects should be advised to avoid routine household contact [CONTACT_204972]/attenuated vaccine components. General guidelines suggest that a study subj ect’s 
exposure to household contacts should be avoided for the below stated time periods:
Varicella or attenuated typhoid fever vaccination –avoid contact [CONTACT_756942] 4 weeks following vaccination
Oral polio vaccination 
–avoid contact [CONTACT_756943] 6 weeks following 
vaccination
Attenuated rotavirus vaccine –
avoid contact [CONTACT_756943] 10 days 
following vaccination
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 48 12July2018Inhaled flu vaccine – avoid contact [CONTACT_756943] 1 week following 
vaccination
Inactivat ed vaccines (such as 
non-liveflu vaccines) should be administered according to 
local vaccination standards whenever deemed medically  appropriate by [CONTACT_093] ; 
however, there are no available data on the concurrent use of filgotinib, GS-9876,
orGS-
[ADDRESS_1036043] s(if any )on immune responses following 
vaccination.
5.10. Investigational Medicinal Product Accountability and Disposal or Return
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drugs. This includes acknowledgement of receipt of each shipment of IMP (quantity and 
condition). All partially  used orunused study  drug sdispensed to subjects must be returned to the 
site.
Study  drug accountability records will be provided to each stud y site to:
Record the date received and quantity  of study  drug s
Record the date, subject number, subject initials, the study  drug number sdispensed
Record the date, quantity of used and unused study  drug sreturned, along with the initials of 
the person recor ding the information.
For additional information about study  drug accountability  and return, refer to Section 9.1.7.
Filgotinib, GS -[ADDRESS_1036044] Enrollment and Treatment Assignment
It is the responsibility  of the I nvestigator to ensure that subjects are eligible to participate in the 
study  prior to randomization/enrollment and throughout the study .
Once consent ha s been obtained, all screening tests and procedures have been assessed, 
andstudy  eligibility  has been confirmed, eligible subjects will be randomized to study  treatment 
as described in Section 3.2.
The study  center will not be activated and allowed to 
screen patients until:
The I RB or IEC have reviewed and approved the study  and the informed consent document
All required regulatory  documents have been submitted to and approved by  [CONTACT_756944]
A master services agreement and/or study  agreement is executed
The site initiation meeting has been conducted b y [COMPANY_009] or its designee . The initiation 
meeting will include, but is not limited to, a review of the protocol, the IB, and the 
Investigator’s responsibilities.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened before randomization to determine eligibility  for participation in the 
study .The screening window may  be extended to up to [ADDRESS_1036045] -reported outcomes, including Global Assessment, VAS assessments are recommended to 
be completed before an y other study  procedures. Invasive study  procedures such as blood draws 
should be done at the end of a study  visit, as much as possible. The following will be performed 
and documented at screening:
Obtain written I nformed Consent
Obtain non- SjS and SjS medical/surgical history , including diagnosis and prior treatments
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 50 12July2018Vital Signs, including weight and height
Complete Phy sical Examination
ESSDAI
PE for domains of ESSDAI , (including glandular exam, ly mph nodes, genera l skin, 
neurologic exam for peripheral neuropath y, pulmonary exam)
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sa mple for:
Urine drug screen (amphetamines cocaine, methadone opi[INVESTIGATOR_2573] s)
Urinaly sis with spot protein/microalbumin/creatinine
Obtain blood samples for:
Serum Pregnancy  Test (female subjects of child bearing potential) or follicle stimulating 
hormone (FSH,as applicable )
TB testing (Quantiferon gold)
CD19+ B cell count (as applicable)
HbA1c, TSH
Hematology
, ESR as applicable, chemistry  and hsCRP
Viral Screening and Reflex PCR
Autoantibodies: anti-SSA or anti -SSB
Complement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM, serum and urine immunofixation
Biomarker samples
Chest X -ray (for subject who had no previous chest X-ray available for review by  [CONTACT_756945] 3 months)
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 51 12July2018VAS
12‑Lead ECG
PFTs (as applicable at 
selected sites)


Adverse Events
Concomitant medications ( All non‑SjS medication used within 30 days of consent (including 
any changes) areto be documented in the eCRF. All prior medica tion(s) used in the treatment 
for SjS or any  other autoimmune disease , are to be documented in the eCRF )
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic after screening for randomization into the study .
Subjects who do not meet the eligibility  criteria will be excluded from randomization and may  be 
considered for rescreening one time for the stud y in consultation with the Sponsor or its 
designee.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, the investigative site is to record all serious adverse events (SAEs), as well as 
any adverse events related to protocol- mandated pr ocedures on the adverse events case report 
form (CRF/eCRF). A ll other untoward medical occurrences observed during the screening 
period, including exacerbation or changes in medical history  are to be captured on the medical 
history  CRF/eCRF. See Section 7Adverse Events and Toxicity  Management for additional 
details.
6.2.2. Day [ADDRESS_1036046]’s eligibility  for the study  has been confirmed, the subject will be 
randomized into the study  to receive one of four study  dosing regimens.
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to D1visit to ensure an approximate 
8-hour fast prior to the blood sample colle ction under fasting condition the next morning.
VAS and subject 
reported QOL s assessments are recommended to be completed before an y other 
study  procedures. Invasive study  procedures such as blood draws should be done at the end of a 
study  visit. The following will be performed and documented at Day 1 prior to dosing:
Randomization
Vital Signs, including weight
CCI
CCI
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
• Symptom-d irected PE 
• ESSDAI (lab results and PFTs as applicable from screening will be used) 
• PE for domains of ESSDAI 
• 28 Swolle n and Tender Joint count 
• Physician 's Global Assessme nt of SjS disease activ ity Final 
Amendment 1 
• Physician 's Global Assessme nt of concomita nt RA or SLE disease activity as applicable 
• Obtain urine sample for: 
-Urinal ysis with spot protein/microalb umin/creat inine 
-Urine Pregnancy Test (female subject s of child bearing potential only) 
-Fasting urine for biomarker 
• Obtain blood sample s for: 
- H emato logy, ESR as applicab le, chemistry and hsCRP 
-Compleme nt (C3, C4, CH 50), and CK 
-Fasting lipid profile , as ou tlined in Appe ndix 6 
-Biomarker sample s 
- A utoantibod ies: deamidated gliadin peptide antibodies (anti DGP lgA or lgG); Anti 
endomysial antib odies (EMA) , RF, CCP ( cyclic citiull inated peptide ), dsDNA, ANA, 
lgA anti tTA (tissue h'ansglutamina se antibodies) 
• VAS 
• Su bject repo1ted QOL s 
• Other questio nnaires addressing disease, activity and fatigue may be provided when and 
where available. 
• Treatment Satisfaction Questionnaire for Medicat ion ( TSQM ) 
CONFIDENTIAL Page 52 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences, Inc. 
• 
• 12-LeadECG 
• 
• 
• 
• 
• 
• 
• Dmg dispe nsing 
• Adverse Events 
• Conco mitant medica tions 
6.3. Randomization Final 
Amendment [ADDRESS_1036047] shou ld be instmcted to hold their dose of study drug s in the mo rning of the visit. The 
dose shou ld be taken at the clinic. 
The following assess ments will be completed at each visit or as speci fied in the Schedule of 
Assess ments in Appendix 2. 
Note: VAS and Subj ect reported QOLs assess ments are recommended to be complete d before 
any other study proce dures. Invasive study procedures such as blood ch·aws shou ld be done at the 
end of a study visit. 
CONFIDENTIAL Page 53 12 July 2018 
Filgotin ib, GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
• Vital Signs, including weight 
• Symptom-dir ected PE 
• 28 Swolle n and Tender Joint count 
• Physician's Global Assess ment of SjS di sease activity Final 
Amendment 1 
• Physician's Global Assess ment of concomita nt RA or SLE disease activity as applicable 
• Obta in urine sample for: 
- Ur inalysis with spot protein/ microalb umin/creat inine 
- Ur ine Pregnancy Test (female su bjects of child bearing potential only) 
• Obta in blood samples for: 
- H emato logy, ESR as applicable, chemistry and h sCRP 
-Compleme nt (C3, C4, CH 50), and CK 
-Biomarker samp les 
• VAS 
• 12-Lead ECG 
• 
• 
• Dmg a ccountability 
• Adverse Events 
• Concomita nt medicat ions 
6.5. Week4 
Subject shou ld be insti11cted to hold their dose of study drug s in the morning of the visit. The 
dose shou ld be taken at the clinic after the pr e-dose PK assessme nt is completed. 
CONFIDENTIAL Page 54 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
The following assess ments will be complet ed at each visit or as specified in the Schedule of 
Assessme nts in Appendix 2. 
Note: VAS and Subject repo1ted QOLs assessme nts are recomme nded to be complete d before 
any other study proce dures. Invas ive study procedures such as blood draws should be done at the 
end of a study visit. 
• Vital Signs, including weight 
• Symptom-dir ected PE 
• ESSDAI 
• PE for domains of ESSDAI 
• 28 Swolle n and Tender Joint count 
• Physician's Global Assess ment of SjS di sease activ ity 
• Physician's Global Assessme nt of concomita nt RA or SLE disease activity as applicable 
• Obta in urine sample for: 
- Ur inalysis with spot protein/ microalb umin/creat inine 
- Ur ine Pregnancy Test (female su bjects of child bearing potential only) 
• Obta in blood samples for: 
- H emato logy, ESR as applicable, chemistry and h sCRP 
-Compleme nt (C3, C4, CH 50), and CK 
-C1yoglob ulins, total lg, quant lgG, lgA, and l gM, sernm and urine immunofixatio n 
- PK samples, collected prior to study diug adininish'atio n (pre- dose) 
-Biomarker samples 
• VAS 
• Su bject repo1ted QOLs 
CONFIDENTIAL Page 55 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 56 12July2018



Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
6.6. Week [ADDRESS_1036048] should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic after the pre- dose PK assessment is completed.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and 
Subject reported QOLs assessments are recommended to be completed before 
any other study  procedures. Invasive stud y procedures such as blood draws should be do ne at the 
end of a stud y visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
CCI
CCI
CCI
CCI
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
• Obtain blood sample s for: 
-Hemat ology, ESR as applicab le, chemistiy and hsCRP 
-Compleme nt (C3, C4, CH 50), and CK 
-PK sample s, collected prior to study chug admini sh'ation (pre-dose) 
-Biomarker sample s 
• VAS 
• Subject repo1ied QOLs 
• 
• 12-Le adECG 
• 
• 
• Dmg dispensing 
• Dmg acco untabili ty 
• Adverse Events 
• Concomita nt medicati ons 
6.7. Week12 Final 
Amendment [ADDRESS_1036049] (no food or ch·ink, except wate r), starting from midni ght 
(00:00) or earlier, as approp riate, on the evening prior to Week [ADDRESS_1036050] ion under fasting conditio n the next morning. 
The following assess ment s will be comp leted at each visit or as specified in the Schedule of 
Assessme nts in Appendix 2. 
CONF IDENTIAL Page 57 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 58 12July2018Note: VAS and Subject reported QOL assessments are recommended to be completed before an y 
other study  procedures. Invasive study  procedures such as blood draws should be done at the end 
of astudy  visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Fasting urine for biomarker
Obtain blood samples for:
Hematology , ESR as applicable, chemist ry and hsCRP
Viral Monitoring for HCV as applicable (see Exclusion criteria, 
Section 4.3)
Autoantibodies: deamidated gliadin peptide antibodies (ant i DGP IgA or IgG); Anti 
endomy sial antibodies (EMA), RF, CCP, dsDNA, ANA, SSA, SSB, IgA anti tTA (tissue 
transglutaminase antibodies)
Complement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM, serum and urine immunofixation
Fasting lipid profile
PK samples, collected prior to study  drug administration (pre -dose)
Biomarker samples
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 59 12July2018VAS
Subject reported QOLs
TSQM

12‑Lead ECG
PFT
s(at selected sites)






Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
6.8. Week [ADDRESS_1036051]-dose biomarker samples can be drawn approximately 2 hours 
after dose.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and outcomes assessments are recommended to be completed before an y other stud y 
procedures. Invasive study procedures such as blood draws should be done after VAS and 
outcome assessments.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 60 12July2018Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly
sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Complement (C3, C4, CH50), and CK
PK samples will be collected approx imately  2hours post dose
Biomarker samples
VAS
Subject reported QOLs

Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
CCI
Filgotinib, GS -[ADDRESS_1036052] (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the ev ening prior to Week [ADDRESS_1036053] prior to the blood sample collection under fasting condition the next morning.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and outcomes assessments are recommended to be completed before an y other stud y 
procedures. Invasive study procedures such as blood draws should be do
ne at the end of a stud y 
visit.
Randomization , subjects on placebo will be re ‑randomized 1:1 :1to either filgotinib , or 
GS-9876 or GS- 4059
Vital Signs, including weight
Complete Phy sical Examination
ESSDAI
PE for domains of ESSDAI
28 Swol len and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Preg nancy  Test (female subjects of child bearing potential only )
Fasting urine for biomarker
Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Viral Monitoring
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 62 12July2018Autoantibodies: deamidated gliadin peptide antibodies (anti DGP IgA or IgG); Anti 
endomy sial antibodies (EMA), RF, CCP, dsDNA, ANA, SSA, SSB, IgA anti tTA (tissue 
transglutaminase antibodies)
Complement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM, serum and urine immunofixation
Fasting lipid profile
PK samples, collected prior to study  drug administration (pre -dose)
Biomarker samples
VAS
Subject reported QOLs
TSQM

12‑Lead ECG
PFT
s (if available, at selected sites)





Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
CCI
CCI
CCI
CCI
CCI
CCI
Filgotinib, GS -[ADDRESS_1036054] should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and outcomes assessments are recommended to be completed before an y other stud y 
procedures. Invasive study procedures such as blood draws should be done at the end of a stud y 
visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Obtain blood samples for:
Hematology
, ESR as applicable, chemistry  and hsCRP
Complement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM,serum and urine immunofixation
Biomarker samples
VAS
Subject reported QOLs
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 64 12July2018


Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
6.11. Week [ADDRESS_1036055] should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic.
The following assessments will be completed at each visit or as spe cified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and 
Subject reported QOL assessments are recommended to be completed before an y 
other study  procedures. Invasive study  procedures such as blood draws should be done at the end 
of a study  visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
CCI
CCI
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 65 12July2018Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Complement (C3, C4, CH50), and CK
Biomarker samples
VAS
Subject reported QOLs



Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
12‑Lead ECG
6.12. Week [ADDRESS_1036056] should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic after t he pre -dose PK assessment is completed.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and outcomes assessments are recommended to be completed before an y other stud y 
procedures. Invasive study procedures such as blood draws should be done at the end of a stud y 
visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
CCI
CCI
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 66 12July2018PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as appl icable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Viral Monitoring
Compl ement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM, serum and urine immunofixation


VAS
Subject reported QOLs
TSQM

12‑Lead ECG



Drug dispensing
CCI
CCI
CCI
CCI
CCI
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 67 12July2018Drug accountability
Adverse Events
Concomitant medica tions
6.13. Week [ADDRESS_1036057] should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: VAS and 
Subject reported QOL assessments are recommended to be completed before an y 
other study  procedures. Invasive study  procedures such as blood draws should be done at the end 
of a study visit.
Vital Signs, including weight
Symptom ‑directed PE
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as app
licable
Obtain urine sample for:
Urinaly sis with spot protein/ microalbumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Complement (C3, C4, C H50), and CK
Biomarker samples
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 68 12July2018VAS
Subject reported QOLs

Drug dispensing
Drug accountability
Adverse Events
Concomitant medications
6.14. Week 48/Early Termination (ET)
If a subject discontinues study , every  attempt should be made to perform the required study -
related ET visit and Follow-up visit procedures.
Subject should be instructed to hold their dose of study drugs in the morning of the visit. The 
dose should be taken at the clinic.
Subjects should be instructed to fast (no food or drink, except water [including for study  drug 
intake] ), starting from midnight (00:00) or earlier, as appropriate, on the evening prior to 
Week 48/ET visit to ensure an approximate [ADDRESS_1036058] prior to the blood sample collection 
under fasting condition the next morning.
The following assessments will be completed at each visit or as specified in the Schedule of 
Assessments in Appendix 2.
Note: 
VAS and Subject reported QOL assessments are recommended to be completed before an y 
other study  procedures. Invasive study  procedures such as blood draws should be done at the end 
of a study  visit.
Vital Signs, including weight
Complete Phy sical Examination
ESSDAI
PE for domains of ESSDAI
28 Swollen and Tender Joint count
Physician’s Global Assessment of SjS disease activity
Physician’s Global Assessment of concomitant RA or SL E disease activity as applicable
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 69 12July2018Obtain urine sample for:
Urinaly sis with spot protein/ microal bumin/creatinine
Urine Pregnancy  Test (female subjects of child bearing potential only )
Fasting urine for biomarker
Obtain blood samples for:
Hematology, ESR as applicable, chemistry  and hsCRP
Viral Monitoring
Autoantibodies: deamidated gliadin peptide ant ibodies (anti DGP IgA or IgG); Anti 
endomy sial antibodies (EMA), RF, CCP, dsDNA, ANA, SSA, SSB, IgA anti tTA (tissue 
transglutaminase antibodies)
Complement (C3, C4, CH50), and CK
Cryoglobulins, total Ig, quant IgG, IgA, and IgM, serum and urine immunofixation
Fasting lipid profile


VAS
Subject reported QOLs
TSQM

12‑Lead ECG
PFTs (
if available, at selected sites)



CCI
CCI
CCI
CCI
CCI
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 70 12July2018
Drug accountability
Adverse Events
Concomitant medications
6.15. Follow -up Visit
The following procedures will be completed [ADDRESS_1036059]’s last dose of study  
treatment.
Vital Signs, including weight
Symptom ‑directed PE
Urine Pregnancy  Test (female subjects of child bearing potential only )
Physician’s Global Assessment of SjS disease activity
Physician’s G lobal Assessment of concomitant RA or SL E disease activity as applicable
Obtain blood sample for :
hematology , ESR as applicable, chemistry  and hsCRP
Biomarker samples
VAS
12‑Lead ECG
Adverse Events
Concomitant medications
6.16. Study Assessments
This study consists of
14scheduled visits plus a follow up visit 4 weeks after study  drug is 
stopped, with total study duration of 48weeks (+4 weeks) .
Thestudy procedures tobe conducted foreach subject enrolled inthestudyaredescribed in the
following sections
.Inaddition, Appendix 2presents thestudy procedures intabular form.
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 71 12July20186.16.1. Patient Reported Outcomes: Visual Analogue Scales and Questionnaires
PRO s, including Visual Analogue Scales (VAS) and questionnaires, are to be completed by  [CONTACT_1560] (where local language questionnaires are available) andshould be recommended to be 
completed before any other study procedures. Please refer to schedule of assessments in 
Appendix 2for the time points for which all PRO assessments are to be completed.
[IP_ADDRESS]. Global Assessment of Disease Activity
The subject will complete a Global Assessment of Disease Activity , recorded on a 0-100 mm
VAS , with 0 indicating “no Sjogren’s S yndrome activity ” and 100 indicating “ most severe 
Sjogren’s S yndrome activity ”.
For subjects who have concomitant RA or SL E, a second global disease activity  VAS will be 
completed b y the subject .
For subjects with concomitant RA: The Global Assessment of Disease Activity  will be recorded 
on a 0-100 mmVAS, with 0 indicating “no Rheumatoid arthritis activity ” and 100 indicating 
“most severe Rheumatoid arthritis activity ”.
For s ubjects with concomitant SL E: The Global Assessment of Disease Activity  will be recorded 
on a 0-100 mmVAS, with 0 indicating “no SLEactivity ” and 100 indicating “ most severe SL E
activity ”.
[IP_ADDRESS]. Assessment of Vaginal Dryness, Ocular Dry ness and Oral Dryness
Subjects will complete an assessment of vaginal dryness, ocular dry ness and of oraldryness. 
These assessments will be recorded on 0- 100mmVAS’s, with 0 indicating “no dry ness” and 
100indicating “ most severe dryness”.
[IP_ADDRESS]. Assessment of Pain and Fatigue
Subjects will complete an assessment of overall pain and fatigue related to the underl ying 
disease . These assessments will be recorded on 0 -100 mmVAS’s, with 0 indicating “no 
pain” /”no fatigue” and 100 indicating “ most intense pain” /”most severe fatigue” .
[IP_ADDRESS]. FACIT -Fatigue Scale
Fatigue will be assessed using the Functional Assessment of Chronic Illness Therap y-Fatigue 
(FACIT -fatigue )scale. The FACIT -fatigue scale measures an individual’s level of fatigue during 
their usual daily  activities over the past week. It consists of 13 questions with a 7 -day recall 
period on a 5- point Likert scale, with 0 indicating “not at all” and 4 indicating “very  much”.
Thetotal score ranges from 0 to 52. Higher scores indicate a better the quality  of life.
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
[IP_ADDRESS]. 36-Item Short-fonn Health Survey Final 
Amendmen t 1 
The SF-36 is a h ealth related quali ty of life instrnmen t consisting of 36 questions belonging to 
8 domain s in 2 compo nents and covers a 4-week recall period : 
• phys ical well-being : 4 do main s: physical functioning (10 items) , role physical (4 items) , 
bodil y pain (2 items), and general health percepti ons (5 items) 
• mental well-bein g: 4 doma ins: vitality (4 items), social functi oning (2 items) , role emotional 
(3 items) , and mental health (5 items) . 
The remainin g item (health transition) is n ot pali of the above domain s, but is kept separately . 
These scales will be rescaled from O to 100 ( conve 1iing the lowe st possible score to O and the 
highe st possible score to 100), with higher scores indicating a bette r quali ty of life. The SF-36 is 
not disease specific and has been validated in numerou s health states . 
[IP_ADDRESS]. Explorato1y Patient Repo1ied Outcome s 
[IP_ADDRESS]. EULAR Sjogre n's Syndrome Patient Repo1ied Index 
EULAR Sjogre n 's Syndrome Patient Repo1ied Index (ESS PRI) is comp leted by [CONTACT_756946] 0-10 : pain, fatigue and 
diyne ss, the final ESSPRI score is the mean of all three scores and therefor e also between 0-10. 
[IP_ADDRESS]. Treatment Satisfaction Questionnair e for Medication 
The TSQM is a compos ite measure based on the subject's rating of medication effectiveness, 
side effects , and convenie nce. At Day 1, this questionnaire will be used to assess prior 
medicati ons us ed to treat the subject 's SjS. At all other time points, specified in the schedule of 
assessments in Appendix 2, the TSQM will be used to assess the subject's opi[INVESTIGATOR_756918] s. Site staff should remin d the subject of which Sj S diug s they sho uld be evaluating at each 
visit. 
[IP_ADDRESS]. Oral Health Impact Profile 
The Oral Health Impact Profile (OHIP- 14) has been endorsed as a disease specific QOL and 
measures aspects directly related to oral health and functi on independent of other prob lems 
assoc iated with SjS in [ADDRESS_1036060] of Dry  Eye on Every day Life (IDEEL) is a dryeyequestion naires, that evaluates QOL 
insubjects with dryeyedisease .It covers [ADDRESS_1036061] on Daily  Life, and Dry  Eye Treatment Satisfaction, that allow 
a comprehensive evaluation of the burden of the dry ey e condition on patients with SjS.
[IP_ADDRESS]. Profile of Fatigue and Discomfort -Sicca S ymptoms I nventory
Profile of Fatigue and Discomfort -Sicca S ymptoms I nventory  (PROFAD -SSI-SF) is 
questionnaire developed specificall y to assess fatigue in SjS patients with 19 questions.
6.16.2. Physician Reported Outcomes: Visual Analogue Scales , Joint Exam and 
Disease Activity Index
Physician reported outcomes, including VAS, joint exam and disease activity  index , are to be 
completed b y the ph ysician, independentl y of the subject’s responses to anyPRO assessments. 
Please refer to schedule of as
sessments in Appendix 2for the time points for which all 
assessments are to be completed.
[IP_ADDRESS]. Physician Assessment of Disease Activity
The evaluating ph ysician should com plete the global assessment independently  ofthe subject’s 
assessments .TheGlobal Assessment of Disease Activity  will be recorded on a 0-100 mmVAS, 
with 0 indicating “no Sjogren’s S yndrome activity” and 100 indicating “ most severe Sjogren’s 
Syndrome acti vity.”
For subjects who have concomitant RA or SL E, a second global disease activity  VAS will be 
completed b y the provider.
For subjects with concomitant RA: The Global Assessment of Disease Activity  will be 
completed b y the provider on a 0-100 mmVAS, with 0 indicating “no Rheumatoid arthritis 
activity ” and 100 indicating “ most severe Rheumatoid arthritis activity ”.
For subjects with concomitant SL E: The Global Assessment of Disease Activity  will be 
completed b y the provider on a 0-100 mmVAS, wit h 0 indicating “no SLE activity ” and 
100indicating “ most severe SLE activity ”.
[IP_ADDRESS]. Evaluation of Disease Activity: Tender and Swollen Joint Counts
Sites will complete an assessment of tenderness and swelling for [ADDRESS_1036062]; however, if a rheumatologist is not available, he/she should be a 
health care worker with experience in performing joint assessments. The subject’s joint 
assessor 
should remain the same throughout the stud y, as much as po ssible.
[IP_ADDRESS]. EULAR Sjogren’s Sy ndrome Disease Activity  Index
EULAR Sjogren’s Sy ndrome Disease Activity  Index (ESSDAI ) is a disease activity  instrument 
to measure disease activity  of primary  Sjogren’s Sy ndrome. It consists of 12domains and each 
domain is divide d into 3 –4 levels of activit y (Appendix 8). Definition of each activity  level is 
provided b y
 a detailed description of what should be considered in that item. The ESSDAI  
should be filled out by  [CONTACT_322127] .
6.16.3. Pulmonary Function Testing
[IP_ADDRESS]. Spi[INVESTIGATOR_756919] (at selected sites) . 
Please refer to schedule of assessments in Appendix 2for the time points atwhich spi[INVESTIGATOR_756920] . The following measurements areperformed atthe visits where spi[INVESTIGATOR_756921] , where available
Vital capac ity (VC)
Forced vital capacit y (FVC)
Forced expi[INVESTIGATOR_47348] (FEV) at timed intervals of 0.5, 1.0 (FEV 1), 2.0, and 3.0 
seconds
Forced expi[INVESTIGATOR_11311] 25–75% (FEF 25–75)
6.16.4. Clinical Laboratory Evaluations
Hematology , chemistry , urinaly sis(with spot protein/ microalbumin/creatinine ), endocrine, 
serology , drug screen, 
hsCRP, TB testing and pregnancy assessments will be carried out as per 
laboratory  assessment table in Appendix 6.
All females of childbearing potential will have urine pregnancy  testing every  4week s during 
their study  participation . During the periods where study  visits are every  6-8week s, women of 
childbearing potential should continue to have pregnancy  tests every  4week s, using home 
pregnancy
 urine tests, which will be provided to them. The site will call the subject every  
4week s to obtain results of these pregnancy  tests and will record the information in the source 
documents and CRF. If a positive urine pregnancy test is reported, the subject will be asked to 
stop all study  medications and return to the clinic for a serum pregnancy  test.
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. Final 
Amendmen t 1 
Plasma concentrntions of filgotinib (and its metabo lite, GS-829845) , GS- 9876, and GS-40 59 will 
be measured and PK param eters detennin ed. 
PK samples will be collected pri or to s tudy drng admini stration (pre-dose) at Weeks 4, 12, and 
24; anytime in relation to last study drng admini stration at Wee ks 8, 36, and 48/E T visi t. At 
Wee k 18, PK samples will be collected approx imately 2 ho urs after study chug achnini stration 
(post dose) . 
The samples will be used to evaluate PK of study chug and m ay also be used to measure protein 
binding of filgotinib, GS-987 6, or GS- 4059 . Plasma concentrations of other m etabolites may be 
determin ed, as applicable. 
Refer to the centrnl laborato 1 y instrnction manual for information on collection and shipm ent of 
required study samples. 
6.16.5. Salivary Flow Measurements 
6.16.6. Tear Production 
6.16.7. Parotid Gland Ultrasound 
CON FIDENTIAL Page 75 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protoco l GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
6.16.8. Vital Signs 
Vital signs will be m easured at the time points indicated in the study proced ures table 
(Appendix 2). Final 
Amendment [ADDRESS_1036063] 
Paper questionnaires will be considered source documents. 
6.16.10. Physical Examination 
A physical examin ation sho uld be per fonned at the time points indicated in the study proced ures 
table (Appendix 2). 
Any changes from B aseline will be recorded. Heig ht should be measured at Screening only 
(subjects sho uld rem ove shoes). At Screening, Wee k 24, and Week 48 (or at ET), a complete 
physical examin ation sho uld be perfo1med. Symptom~ irected physica l examinations sho uld be 
perfo1med at all other vis its. Physical exam evaluating the domains of the ESSDAI should be 
perfo1med at the time points indicated in the schedule of assess ments (Appendix 2). 
Weight is measured at all visits. 
6.16.11. Other Assessments 
12-lead Electrocardiogram 
A resting 12-lead ECG sho uld be perfo1med at the time points indicated in the study proced ures 
table (Appendix 2). 
The ECG should be obtained after the su bject has been resting in the supi[INVESTIGATOR_19636] 5 min 
and will include HR, inter-beat (RR), QRS, unco1Tected QT, morphology, and rhythm analysis. 
QT interval co1Tected for HR acco rding to F ridericia (QTcF) will be derived during the st atistical 
analysis. ECGs will be interpreted by [CONTACT_756947] r esults will be 
entered into the eCRF. 
CONFIDENTIAL Page 76 12 July2018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
Ophthalmolo gic Exam s 
CONF IDENTIAL Page 77 Final 
Amendment 1 
12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 78 12July20187. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) i s any  untoward medical occurrence in a clinical study  subject administered
a medicinal product ,which does not necessaril y have a causal relationship with th etreatment. 
AnAE can therefore be any  unfavorable and/or unintended sign, s ymptom, or disease tem porally  
associated with the use of a medicinal product, whether or not considered re lated to the 
medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of 
protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , 
oroccupational exposure .Preexisting events that increase in severity  or change in nature during 
or as a consequence of participation in the clinical study  will also be considered AEs.
AnAE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without cl inical sequelae (see Section 7.7.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_059] o r prolongation of existing hospi[INVESTIGATOR_756922], GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 79 12July2018Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  life- threatening
or result in death or hospi[INVESTIGATOR_122011]. Medical and scientific 
judgment must be exercised to determine whether such an event is a reportable under 
expedited reporting rules. 
Example s of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; anddevelopment of drug dependency  or 
drug abuse. For the avoidanc e of doubt, infections resulting from contaminated medicinal 
product will be considered a m edicall y important e vent and subject to expedited reporting 
requirements.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, 
analternative causalit y must be provided (eg, pre -existing condition, underly ing disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_756948] .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the cont ext of adverse event reporting.
The relationship to study  procedures (eg, invasive procedures such as venipuncture or b iopsy) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venipun cture )
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 80 12July20187.2.2. Assessment of Severity
The severit y of AEs will be graded using the modified Common Terminology  Criteria for 
Adverse Events ( CTCAE ), version 4.03. For each epi[INVESTIGATOR_1865], the highest grade attained should be 
reported.
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: 
Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life- threatening) or Grade 5 
(fatal) to describe the maximum intensity  of the adverse event.
For purposes of consistency  with the CTCAE, these intensity  grades a re defined in Table 7-1and 
Appendix 4.
Table 7-1. Grading of Adverse Event Severity
Grade Adjective Description
Grade 1 Mild Asymptomatic or mild symptoms; 
clinical or diagnostic observations 
only; intervention not indicated
Grade 2 Moderate Local or noninvasive intervention 
indicated; limiting age -appropriate 
instrumental ADL *
Grade 3 Severe Severe or medically significant but 
not immediately life -threatening; 
hospi[INVESTIGATOR_24599]; disabling; 
limiting self -care ADL**
Grade 4 Life-threatening Urgent intervention indicated
Grade 5 Death Death related AE
* Activities of Daily Living (ADL) Instrumental ADL refer to opening preparing meals, shoppi[INVESTIGATOR_3112], 
using the telephone, managing money, etc.
** Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for C ollection Prior to S tudy D rug Initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to 
protocol -mandated procedures.
Filgotinib , GS-[ADDRESS_1036064] be repo1ted to the CRF/eCRF database 
as instructed . 
All AEs should be followed up until resolution or until the adverse event is stable , if possible . 
[COMPANY_009] Sciences may request that ce1tain AEs be followed beyo nd the protocol defined follow up 
period. 
Seriou s Ad verse Events 
All SAEs, regardless of cause or relatio nship, that occur after the subject first consents to 
paiticipate in the study (ie, signing the infonned consent) and throughout the duration of the 
study , including the protocol -required post tr·eatinent follow-up period, must be reported to the 
CRF /eCRF database and [COMPANY_009] PVE as instr11cted. This also includes any SAEs resulting from 
protocol -associated proced ures perfonned after infonned consent is signed. 
Any SAEs and deaths that occur after the post tr·eatine nt follow-up visit but within 30-days of the 
last dose of study IMP, regai·d less of causality , shou ld also be reported . 
Investigators ai· e not obligated to active ly seek SAEs after the protocol defined follow up period; 
howeve r, if the investigator learns of any SAEs that occur after study pa1ticipation has concluded 
and the event is deemed relevant to the use of IMP, he/she sh ould promptly docume nt and repo1 t 
the event to [COMPANY_009] PVE. 
• A ll AEs and SAEs will be recorded in the CRF /eCRF database within the timeli nes outlined 
in the CRF /eCRF completion guideline. 
Electi-o nic Serious Adverse Event (eSAE) Repo1t ing Process 
• Site perso nnel record all SAE data in the eCRF database and from there tr·ansmit the SAE 
infonnatio n to [COMPANY_009] PVE within 24 hours of the investigator's knowledge of the event. 
Detai led instructions can be found in the eCRF completion guidelines. 
• If for any reaso n it is not possib le to record the SAE infonnatio n electr·onically, ie, the eCRF 
database is not functioning, record the SAE on the pape r serious adverse event report ing 
fo1m and su bmit within 24 hours as descr ibed above . 
[COMPANY_009] PVE Fax: IPI[CONTACT_4002] 
E-mail: IPPU 
• As soon as it is poss ible to do so, any SAE repo1ted via paper must be ti-anscr ibed into the 
eCRF Database accord ing to instructions in the eCRF completio n guidelines. 
CONFIDENTIAL Page 81 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 82 12July2018If an SAE has been reported via a paper form because the eCRF database has been locked, 
nofurther action is necessary .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline.
For fatal or life -threa tening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the tra ceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medicat ion section of the subject’s CRF/ eCRF and the event description section of the SAE 
form.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Tria ls Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs , serious adverse drug reactions (SADRs) ,
or suspected unexpected serious adverse r eactions (S[LOCATION_003]Rs). Inaccordance with the EU 
Clinical Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide 
regulatory  agencies and the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs as 
outlined in c urrent regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_386045].
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC 
of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , and urinal ysis) independent of the underl ying 
medical condition that require medic al or surgical intervention or lead to study  drug interruption, 
modification, or discontinuation must be recorded as an AE, as well as an SAE, if applicable. 
Inaddition, laboratory  or other abnormal assessments (eg, electrocardiogram, x
-rays, vital signs)
that are associated with signs and/or s ymptoms mu st be recorded as an AE or SAE if they  meet 
the definition of an AE or SAE as described in Sections 7.1.[ADDRESS_1036065] the syndrome or diagnosis (i.e., anemia) 
notthe laboratory result (i.e., decreased hemoglobin).
Severity  of laboratory  abnormality should be recorded and graded according to the modified 
CTCAE Grading Scale Version 4.03, which can be found in Appendix 4.
For adverse events associated with laboratory
 abnormalities, the event should be graded on the 
basis of the clinical severity  in the context of the underly ing conditions; this may or may  notbe 
in agreement with the grading of the laboratory  abnormality .
7.6. Toxicity Management
Treatment -emergent toxicities will be noted by  [CONTACT_756949]. Whether or not considered treatment -related, 
all subjects experiencing AEs should be monitored as clinically  indicated, until sy mptoms 
subside, and until any abnormal laboratory  values have resolved or returned to baseline levels or 
are considered irreversible, or until there is a satisfactory  explanation for the changes observed.
All clinical and clinicall
y significant laboratory toxicities will be managed according to uniform
guidelines detailed in Appendix 3and as outlined below.
Grade [ADDRESS_1036066] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as 
complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
Occupa tional exposure is defined as exposure to a medicinal product as a result of one's 
professional or non- professional occupation.
7.7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study drug follow - up 
period, [COMPANY_009] PVE using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy .
Refer to Section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to termi nate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in [ADDRESS_1036067] information is as follows: 
Email:  and Fax: 
[COMPANY_003]
[COMPANY_003]
Filgotinib, GS -[ADDRESS_1036068] also b e reported and relevant information should be submitted to [COMPANY_009] PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. If the end of the pregnancy  occurs 
after the stud y has been completed, the outcome should be reported directly  to [COMPANY_009] PVE , fax 
number  or email 
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] PVE within [ADDRESS_1036069] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications.
Special situations involving non-[COMPANY_009] concomitant medications does not need to be reported on 
the spe cial situ ations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form.
Any inappropriate use of concomitant medications prohibited by  [CONTACT_437210] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
[COMPANY_003]
[COMPANY_003]
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 86 12July20188. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is:
To assess the efficacy  of filgotinib, GS -9876 and GS- 4059 in adult subjects with active SjS.
The secondary  objectives of this study  are:
To assess the safet y and tolerability of filgotinib, GS -9876 and GS -4059 in adult subjects 
with active SjS
To assess the effect of filgotinib, GS -9876 and GS- 4059 on patient reported outcomes in 
active SjS , including fatigue, disability  and quality  of life
The explorator y objectives of this study  are:
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects at who fulfill response criteria as outlined in 
Section 2.
8.1.3. Secondary Endpoint
Secondary  endpoint sare:
Change from baseline in ESSDAI  at Week 12 
Change from baseline in ESSPRI  at Week 12 
Change from baseline in ESSDAI  at Week 24
Change from baseline in ESSPRI  at Week 24
CCI
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 87 12July20188.1.4. Exploratory Endpoints
CCI
Filgotinib , GS- 9876 and GS-4059 
Protocol GS-US-445-4189 
[COMPANY_009] Sciences, Inc. 
8.2. 
8.2.1. 
[IP_ADDRESS]. Anal ysis Convention s 
Anal ysis Sets 
All Rando mized Final 
Amendment [ADDRESS_1036070] listings. 
[IP_ADDRESS]. Efficac y 
The primai y analysis set for efficac y anal yses will be the Full Analysis Set, which includes all 
randomized subject s who r eceive d at least one dose of study chug. 
[IP_ADDRESS]. Safety 
The pr ima1 y analysis set for safety analyses wi ll be the Safet y Analysis Set, which includes all 
subjects who r eceived at least one d ose of s tudy chug. 
[IP_ADDRESS]. [IP_ADDRESS].1. 
[IP_ADDRESS].2. Phaimacok inetics 
PK Substudy Analysis Set 
PK Analysis Set 
The pr ima1 y analysis set for PK analyses will be the PK Analysis Set, which includes all subject s 
in the Safety Analysis Set who h ave at least 1 no n-missing PK con centrat ion data for GS-9 876, 
filgotinib, GS- 4059, an d/or their metabo lite(s). 
[IP_ADDRESS]. Biomai·ker 
The prima1 y an alysis set for biomai·ker analyses will be the Biomar ker Analy sis Set, which 
include s all subject s in the Safety Anal ysis Set who have at least one evaluable measurement 
available at any time point for a given biomai·ker of intere st. 
CONFIDENTIAL Page 88 12 July 2018 
Filgotinib, GS-9876 and GS-4059 
Protocol GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
8.3. Data Handling Conventions Final 
Amendmen t 1 
Phaimacokinetic conce ntrntion values and PK parameter values below the limit of quantitation 
(BLQ ) will be presented as "BLQ " in the data listings. BLQ values that occur prior to the first 
dose will be treated as 0, BLQ values at all other time points will be treated as 1/2 of the l ower 
limit of quantitation (LLOQ) . 
Laborato1 y data that ai·e continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or uppe r limit 
minu s or plus one significant digit , respective ly ( eg, if the result of a continu ous laborato [ADDRESS_1036071] is 
< 20, a value of 19 will be assigned; if the result of a continuous la borat o1 y test is < 20.0, a value 
of 19.9 will be assigned). 
8.4. Demographic Data and Baseline Characteristics 
Demograp hic and baseline measurement s will be summarized using standard descriptive 
statistics inclu ding sample size, mean , SD, median , Ql , Q3, minimum , and maximum for 
continuous vai·iables and numb er and percent ages of subjects for catego rical vai·iables. 
Demograp hic summai · ies will include sex, race/ethnicity, and age. 
Baseline chai·acte ristics will include a summai y of at least PRO s, ESSDAI , disease duratio n 
(time from diagnosis), , 28-joint count, cune nt or prior use of DMARD(s), and oral 
co1iicostero ids. 
8.5. 
8.5.1. Efficacy Analysis 
Primar y Analysis 
The prima1 y en dpoint is the prop o1iion of subject s fulfillin g respo nse criteria (as outlined in 
Section 2). The prima1y analys is will consist of a s uperiority test of each of filgotinib, GS-[ADDRESS_1036072] dose of study  drug + 30 days will be summarized by  [CONTACT_71930] (according to the 
IMP study  drug received).
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug
administration page of the eCRF . Exposure data will be summarized by  [CONTACT_1570].
Duration of e xposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug, inclusive, regardless of temporary interruptions in study  drug 
administration and summarized by  [CONTACT_1570].
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -emergent adverse events (TEAEs) are defined as one or both of the following:
Any AEs with an onset date on or after the study drug start date and no later than 30 day s 
after permanent discontinuation of study  drug.
Any AEs leading to premature discontinuation of study  drug.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (by [CONTACT_2946], 
and PT) will be provided by  [CONTACT_1570].
8.6.3. Laboratory 
Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and 
maximum) by  [CONTACT_1570]. Absolute values and change from baseline at all scheduled time
points will be summarized.
Graded laboratory  abnormalities will be defined using CTCAE 4.[ADDRESS_1036073] dose of study 
drug plus 30 days, will be summarized by  [CONTACT_3148].
Filgotinib , GS-9876 and GS-4059 
Protoco l GS-US-445 -4189 
[COMPANY_009] Sciences , Inc. 
8.7. Pharmacokinetic Analysis Final 
Amendment 1 
Plasma concentrntions of filgotinib, the active metabo lite of filgotinib (GS-8298 45), GS-9876 , 
and GS-4059 will be listed and summari zed using descriptive statistics ( eg, sampl e size, 
arithm etic me an, geometric me an, % coefficient of variation, s tandard deviation, me dian, 
minimum , and maximum ). 
Plasma concentrntions of GS- 9876 metabolite(s), other filgotinib metabo lite(s), and/or GS-40 59 
metabo lite(s) may also be detennin ed and analyzed. 
8.8. Biomarker Analysis 
For analysis of bioma rkers (eg, cytokines, chemo kines, leukocyte flow cytometiy , etc.) 
collected at baseline and post-baseline visi ts, the b aseline levels and the mo dulati on pattern upon 
ti·eatinent, includin g chan ge over time from b aseline l evels, w ill be evaluated by [INVESTIGATOR_62300]·eatinent group . 
Descriptive statistics will be provided at each s amplin g time, by [INVESTIGATOR_62300]·eatinent group. A dditi onally 
graphical summari es, e.g. mean+/-SD, me dian+/-interquartil e range (QI, Q 3), box plots, and 
scatter plots to explore con-elations betwee n different bio mark ers m ay also be generated, 
as neede d. These graphs m ay be generated for raw values as well as change from baseline, 
as appropriate. 
CONFIDENTIAL Page 91 12 July2018 
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 92 12July20188.9. Sample Size
Based on results of prior SjSstudies, assuming a response rate of 70% for an active arm and30% 
for the placebo arm at Week 12, approximately  35 evaluable subjects will be needed in each arm 
to achieve 
85% power to detect a significant diffe rence at a 2- sided, 0.05- level. Enrollment of 
approximately  35subjects peramis planned to ensure tha t a sufficient number of subjects is 
available analy sis of the primary  endpoint.
8.10. Analysis Schedule
Theprimary  and secondary  analysis will be conducted after all subjects either complete the
Week [ADDRESS_1036074] , as well as study  investigators and subjects will remain blinded to the individual 
treatment assignments. The final anal ysis will be performed when all subjects complete the study
(as defined in Section 3.5) or premat urely discontinue from the stud y.
Additionally , to assess the safet y and efficacy  of GS -9876, filgotinib and GS-
[ADDRESS_1036075] one representative from 
Clinical Research, Biostatistics, and Pharmacovigilance/Epi[INVESTIGATOR_623] , and may  include other 
personnel as necessary . The [COMPANY_009] intern al unblinded team will be granted access to unblinded 
clinical data including treatment assignment sto closely  monitor study  progress and drug safet y
.
To mitigate the risks of inadvertentl y releasing the treatment information to the sites and 
subjects, the internal team will keep the unblinded information confidential and will not 
communicate the information to the blinded study team, site staff or subjects. Data unblinding 
due to medical emergency will follow standard [COMPANY_009] procedures.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 93 12July20189. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Co uncil for Harmonisation (ICH) guidelines, or with the 
laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in the 
Code of Federal Regulations (CFR) Title 21 part 312 ( 21CFR 312), subpart D, 
“Responsibilities of Sponsors and Investigators,” [ADDRESS_1036076] be provided prior to the 
investigator’s (and an y subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_1036077] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC . The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC an y modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
Filgotinib, GS -[ADDRESS_1036078] current
IRB/IEC approved consent form for documenting written informed consent. Each informed 
consent (or assent as applicable) will be appropriately  signed and dated by  [CONTACT_756950], an dalso by  [CONTACT_537114] b y 
IRB/IEC or local requirements.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject i nitials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC ,or laboratory . Laboratory  
specimens must be labeled in such a way asto protect subject identity  while allowing the 
results to be recorded to the proper subject. Refer to specific laboratory  instructions . 
NOTE :Theinvestigator must keep a screening log showing codes, names, and addresses for all 
subjects screened and for all subjects enrolled in the trial. Subject data will be processed in 
accordance w ith all applicable regulations.
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator 
brochure, this protocol eCRF ,the IMP, and any  other study  information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the cond uct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classif ied into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IEC and governmental approval with corres pondence, informed consent, drug records, 
staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.
Filgotinib, GS -[ADDRESS_1036079]:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, i.e.
, history , phy sical examination, 
andconfirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results 
of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_1036080] approval of a marketing application in 
an ICH region ( i.e., [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no applic ation is filed or if the application is not 
approved for such indication, until [ADDRESS_1036081] consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training for this function is completed in EDC. The eCRF casebook will only  
capture the data required per the protocol schedule of events and pr ocedures. 
TheInclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility  have been received. Subsequent to data entry , a stud y monitor will perform 
source data verification within the EDC sy stem. Sy stem -generated or manual queries will be 
issued to the investigative site staff as data discrepancies are identified b y the monitor or internal 
[COMPANY_009] staff, who routinely  review the data for completeness, correctness, and consistency . 
Thesite coordinator is responsible for responding to the queries in a timely
 manner, within the 
system, either b y confirming the data as correct or updating the original entry , and providing the 
reason for the update (e.g. data entry  error). Original entries as well as any  chang es to data fields 
will be stored in the audit trail of the sy stem. Prior to any  interim time points or database lock 
(asinstructed b y [COMPANY_009]), the investigator will use his/her log in credentials to confirm that the 
forms have been reviewed, and that the entries accuratel y reflect the information in the source 
documents. At the conclusion of the trial, [COMPANY_009] will provide the site with a read -only archive 
copy  of the data entered by  [CONTACT_10867]. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability 
and Return
Where possible, IMP should be destro yed at the site. At th e start of the study , the study  monitor 
will evaluate each stud y center’s IMP disposal procedures and provide appropriate instruction for 
disposal or return of unused IMP supplies. If the site has an appropriate standard operating 
procedure (SOP) for drug destruction as determined by  [CONTACT_10869], the site may  destroy  
used (empt y or partially empty) and unused IMP supplies as long as performed in accordance 
with the site’s SOP. This can occur onl y after the study  monitor has performed drug 
accountability  during an on -site monitoring visit.
A cop y of the site’s IMP Disposal SOP or written procedure (signed and dated by  [CONTACT_978] 
[INVESTIGATOR_1461]) will be obtained for [COMPANY_009] site files. If the site does not have a cceptable 
procedures in place, arrangements will be made between the site and [COMPANY_009] Sciences 
(or[COMPANY_009] Sciences’ representative) for return of unused study  drug supplies.
If IMP is destro yed on site, the investigator must maintain accurate records for al l IMP
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copi[INVESTIGATOR_143346]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 97 12July20189.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y mo nitors, to IRBs /IECs , or to regulatory  authority  or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by [CONTACT_10866]. The investigator must submit a ll protocol modifications to the IRBs/IECs
in accordance with loc al requirements and receive documented IRBs / IECs approval before 
modifications can be implemented. Substantial modifications (as classified by  [CONTACT_756951] 
2001/20/EC) will be submitted and approved b y relevant EU competent authorities, and by [CONTACT_105] -
EU competent authorities as required b y local regulations, prior to implementation.
9.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency (ies). [COMPANY_009] will 
ensure that the report meets the standards set o ut in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least [ADDRESS_1036082] 30 days before submission of t he 
publication or presentation.
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obt ain patent protection if 
deemed necessary .
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 98 12July20189.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings. If requ ired under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  ofthe data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on the m. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) areresolved .
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the [COMPANY_009] medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discont inuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. 
Should this be necessary , both parties will arrange discontinuation procedures and notify  the 
appropriate regulatory  authority (ies), IRBs, and IECs. I n terminating the study , [COMPANY_009] and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 99 12July201810. REFERENCES
Bahjat FR, Pi[INVESTIGATOR_386029], Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally  bioa vailable 
spleen ty rosine kinase inhibitor delay s disease progression and prolongs survival 
in murine lupus. Arthritis Rheum 2008;58 (5):1433-44.
Barr PM, Wei C, Roger J, Schaefer- Cutillo J, Kelly  JL, Rosenberg AF, et al. Sy k inhibition with 
fostamatinib le ads to transitional B ly mphocy te depletion. Clin I mmunol 
2012;142 (3):237 -42.
Braselmann S, Taylor V, Zhao H, Wang S, Sy lvain C, Baluom M, et al. R406, an orall y available 
spleen ty rosine kinase inhibitor blocks fc receptor signaling and reduces immune 
complex-mediated inflammation. J Pharmacol Exp Ther 2006;319 (3):998 -1008.
Coffey  G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, et al. Specific inhibition of 
spleen ty rosine kinase suppresses leukocy te immune function and inflammation in 
animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340 (2):350-9.
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy  JJ, et al. The clinically  active 
BTK inhibitor PCI -[ZIP_CODE] targets B -cell receptor -and chemokine -controlled 
adhesion and migration i n chronic l ymphocy tic leukemia. Blood 2012;119 
(11):2590-4.
de Weers M, Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ, et 
al. The Bruton's t yrosine kinase gene is expressed throughout B cell 
differentiation, from early precursor B cel l stages preceding immunoglobulin gene 
rearrangement up to mature B cell stages. European journal of immunology 
1993;23 (12):3109 -14.
Deng GM, Liu L, Bahjat FR, Pi[INVESTIGATOR_386029], Tsokos GC. Suppression of skin and kidney  disease by  
[CONTACT_386048]- prone mice. Arthritis Rheum 2010;62 
(7):2086-92.
Devauchelle -Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse -Joulin S, et al. 
Improvement of Sjogren's sy ndrome after two infusions of rituximab (anti -CD20). 
Arthritis Rheum 2007;57 (2):310-7.
Fife RS, Chase WF, Dore RK, Wiesenhutter CW, L ockhart PB, Tindall E, et al. Cevimeline for 
the treatment of xerostomia in patients with Sjogren s yndrome: a randomized 
trial. Arch Intern Med 2002;162 (11):1293
-300.
Fox RI . Sjogren's s yndrome. Lancet 2005;366 (9482):321-31.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 100 12July2018Genevier HC, Hinshelwood S, Gaspar HB, Rigley  KP, Brown D, Saeland S, et al. Expression of 
Bruton's t yrosine kinase protein within the B cell lineage. European journal of 
immunology  1994;24 (12):3100-5.
Hutcheson J, Vanarsa K, Bashmakov A, Grewal S, Sajitharan D, Chang BY, et al. Modulating 
proximal cell signaling by [CONTACT_756952]-organ disease in murine lupus. Arthritis research & therap y 2012;14 
(6):R243.
Kruszka P, O'Brian RJ. Diagnosi s and management of Sjogren s yndrome. Am Fam Physician 
2009;79 (6):[ADDRESS_1036083] maturation. J Biol Chem 2008;283 (17):[ZIP_CODE] -34.
Mariette X, Seror R, Qua rtuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy  and safet y of 
belimumab in primary  Sjogren's sy ndrome: results of the BELISS open -label 
phase II stud y. Annals of the rheumatic diseases 2015;74 (3):526 -31.
Martin F, Chan AC. B cell immunobiology  in disease: evolving concepts from the clinic. Annu 
Rev I mmunol 2006;24:467 -96.
Namour F, Diderichsen PM, Cox E, Vay ssiere B, Van der Aa A, Tasset C, et al. 
Pharmacokinetics and Pharmacokinetic/Pharmacody namic Modeling of Filgotinib 
(GLPG0634), a Selective JA K1 Inhibitor, in Support of Phase IIB Dose Selection. 
Clin Pharmacokinet 2015;54 (8):859-74.
Patel R, Shahane A. The epi[INVESTIGATOR_756923]'s sy ndrome. Clinical epi[INVESTIGATOR_623]  
2014;6:247-55.
[COMPANY_007]. SAL AGEN -5mg tablets. Product Monograph.  2014:
Pi[INVESTIGATOR_566663] J, Meijer JM, Bootsma H, van der Wal JE, Spi[INVESTIGATOR_327130], Kallenberg CG, et al. Clinical 
and histologic evidence of salivary  gland restoration supports the efficacy  of 
rituximab treatment in Sjogren's s yndrome. Arthritis Rheum 2009;60 (11):3251 -6.
Ramos -Casals M, Tzioufas AG, Font J. Primary  Sjogren's s yndrome: new clinical and 
therapeutic concepts. Annals of the rheumatic diseases 2005;64 (3):347 -54.
Rankin AL , Seth N, Keegan S, Andrey eva T, Cook TA, Edmonds J, et al. Selective inhibition of 
BTK prevents murine lupus and antibody -mediated glomerulonephritis. J 
Immunol 2013;191 (9):4540-50.
Rising Pharmaceuticals Inc. Cevimeline - [ADDRESS_1036084] differentiation b y linking RANK and ITAM signals. 
Cell 2008;132 (5):794 -806.
Smith CI , Baskin B, Humire -Greiff P, Zhou JN, Olsson PG, Maniar HS, et al. Expression of 
Bruton's agammaglobulinemia ty rosine kinase gene, BTK, i s selectivel y down -
regulated in T l ymphocy tes and plasma cells. J I mmunol 1994;152 (2):557 -65.
Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and 
anticitrullinated protein antibodies. QJM 2010;103 (3):139-46.
Stone JH, Khosros hahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, et al. 
Recommendations for the nomenclature of IgG4 -related disease and its individual 
organ s ystem manifestations. Arthritis Rheum 2012;64 (10):3061 -7.
Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, et al. Bruton ty rosine kinase 
inhibition is a novel therapeutic strategy  targeting tumor in the bone marrow 
microenvironment in multiple my eloma. Blood 2012;120 (9):1877-87.
The Sjogren's Sy ndrome Foundation. Ask the SSF Staff: Treating Primary  vs. Secondary  
Sjögren’s. Available at: 
http://info.sjogrens.org/conqueringsjogrens/bid/359061/AsktheSSFStaffTreatingP
rimary vsSecondary Sjgrens . Posted December 2014. Accessed: 17 October.  2016.
Tobon GJ, Pers JO, Youinou P, Saraux A. B cell-targeted therapi[INVESTIGATOR_756924]'s s yndrome. 
Autoimmunity  reviews 2010;9 (4):224-8.
Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical 
entity , IgG4 -related disease (IgG4RD): general concept and details. Modern 
rheumatology  / the Japan Rheu matism Association 2012;22 (1):1-14.
Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y, et al. Jak/STAT signaling is involved in 
the inflammatory  infiltration of the kidney s in MRL/lpr mice. Lupus 2010;19 
(10):1171-80.
Wu CH, Hsieh SC, L ee KL , Li KJ, L u MC, Yu CL. Pi[INVESTIGATOR_756925]'s s yndrome in Taiwan --a double -blind, 
placebo-controlled trial. J Formos Med Assoc 2006;105 (10):796-803.
Filgotinib, GS -9876 and GS-4059
Protocol GS -US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 102 12July201811. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Schedule of Activities
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. Common Terminology Criteria for Adve rse Events (CTCAE) v4.03
Appendix 5. Pregnancy Precautions, Definition of Female of Childbearing 
Potential, and Contraceptive Measures
Appendix 6. Laboratory Assessment Table
Appendix 7. American European Consensus Group (AECG) c lassification criteria 
for Sjogren ’sSyndrome
Appendix 8. EULAR Sjogren’s Syndrome Disease Activity Score ( ESSDAI )
Filgotinib, GS-[ADDRESS_1036085] 
FOSTER ClTY, CA [ZIP_CODE] 
[LOCATION_003] 
STUDY ACKNOWLEDGEMENT Final 
Amendment l 
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and 
Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren' s Syndrome 
GS-US-445-4189, Amendment 1, 12 July 2018 
This protoco l has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_756959] a roval. 
Name (Printed) 
Author 
Date 
INVESTIGATOR ST A TEMENT 
l have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. [ADDRESS_1036086] this study as 
outlined here in and will make a reasonable effort to complete the study within the time 
designated . 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_279395] 103 12July20 I8 
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 104 12July2018Appendix 2. Schedule of Assessments Table
Visit window
Screening a
Day 1b
Week 2
Week 4
Week 8
Week 12
Week 18
Week 24
Week 26
Week 28
Week 32
Week 36
Week 42
Week 48/ETc
Follow Up visit
[ADDRESS_1036087]’s last 
study visit d
None None+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
7days+/-
7days+/-
7days+/-
7days
Fasting visit x X x x
IP to be taken at the clinic x x x x X x x x x x x x x
Written Informed Consent x
Randomization xexf
Physical exam  and provider assessments
SjS medical/surgical history, 
including diagnosis and prior 
treatment s,x
Medical /Surgical History
(non-SjS)x
Vital Signs, including weight
and heightgx x x x x X x x x x x x x x x
Complete Physical 
Examinationx x x
Symptom -directed PE x x x x X x x x x x x x
ESSDAI x xyx x X x x x x x x x
PE for domains of ESSDAIhx x x x X x x x x x x x
28Swollen and Tender Joint 
countx x x x x X x x x x x x x x
Physician’s Global Assessment 
of SjS activityx x x x x X x x x x x x x x x
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 105 12July2018Visit window
Screening a
Day 1b
Week 2
Week 4
Week 8
Week 12
Week 18
Week 24
Week 26
Week 28
Week 32
Week 36
Week 42
Week 48/ETc
Follow Up visit
[ADDRESS_1036088]’s last 
study visit d
None None+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
7days+/-
7days+/-
7days+/-
7days
Physician’s Global Assessment 
of concomitant RA or SLE 
disease activity as applicablex x x x x X x x x x x x x x x
Laboratory assessments
Urine drug screenix
Urinalysis with spot protein/
microalbumin/creatinin ex x x x x X x x x x x x x x
Urine Pregnancy Test ( female 
subjects of child bearing 
potential only)x x x x X x x x x x x x x x
Urine for biomarker (fasting) x X x x
Serum Pregnancy Test ( female 
subjects of child bearing 
potential ) or FSHx
TB testingjx
CD19+ B cell countkx
HbA1c, TSH x
Hematology, ESR as 
applicable, chemistry and 
hsCRPx x x x x X x x x x x x x x x
Viral Screening and Reflex 
PCRlx
Viral MonitoringmX x x x
Autoantibodiesnx x X x x
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 106 12July2018Visit window
Screening a
Day 1b
Week 2
Week 4
Week 8
Week 12
Week 18
Week 24
Week 26
Week 28
Week 32
Week 36
Week 42
Week 48/ETc
Follow Up visit
[ADDRESS_1036089]’s last 
study visit d
None None+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
7days+/-
7days+/-
7days+/-
7days
Complement (C3, C4, CH50), 
and CKx x x x x X x x x x x x x x
Cryoglobulins, total Ig, quant 
IgG, IgA, and IgM, serum and 
urine immunofixationx x X x x x x
Lipid profile (fasting)ox X x x
PK samplespx x X x x x x
Blood for Biomarker samplesrx x x x x X x x x x x x x x x
PROs and questionnaires
VAStx x x x x X x x x x x x x x x
ESSPRI x x x x x X x x x x x x x x x
FACIT -Fatigue, OHIP -14, 
PROFAD -SSI-SFux x x X x x x x x x x
SF-36, IDEELux X x x x
TSQM x X x x x
CCI
CCI
CCI
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 107 12July2018Visit window
Screening a
Day 1b
Week 2
Week 4
Week 8
Week 12
Week 18
Week 24
Week 26
Week 28
Week 32
Week 36
Week 42
Week 48/ETc
Follow Up visit
[ADDRESS_1036090]’s last 
study visit d
None None+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
3days+/-
7days+/-
7days+/-
7days+/-
7days
Procedures and Exams
12-Lead ECG x x x x x x x x x x x
Pulmonary function testsvx x x x
Chest X -ray (as applicable)zx
Drug dispensing x x x x x x x x x x
Drug accountability x x x x x x x x x x x x
Adverse Events x x x x x x x x x x x x x x x
Concomitant medicationsxx x x x x x x x x x x x x x x
a Screening window is [ADDRESS_1036091]’s last dose of study drug was >[ADDRESS_1036092] study visit
e Subjects will be randomized on Day 1 based on their use of concomitant medications (y/n: csDMARD and/or oral corticosteroid) and ESSDAI hematological plus biological 
domains score at Day 1, (Y/N: ESSDAI ≥ 2).
f Subjects on placebo will be re -randomized 1: 1:1 to either filgotinib ,or GS -9876 or GS -4059
CCI
CCI
CCI
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US -445-4189 
[COMPANY_009] Science s, Inc. Final 
Amendment 1 
g Heigh t is only required at Visit 1 and subjec ts are to remo ve shoes during measuremen t 
h Exam should include glandular exam , lymph node s, general skin, nem·ologic exam for peripher al nem·opa thy, puhnona1y exam 
Amphe tamine s Cocaine , Methadone Opia tes 
J Quan tiferon gold 
k As a pplic able 
1 Hepa titis B stuface Ag and core Ab, Hepa titis C Ab, reflex HCV RNA , HIV 1 and 2 at Screening 
m Viral moni toring for HCV as applicable (see Excl usion criteria, Section 4.3) 
n At s creening only: anti SSA and anti SSB 
At D ay 1: deamidated gliadin peptide antibodies (anti-DGP IgA or IgG); Anti-end omysial antibodie s (EMA ), RF, CCP, dsDNA, ANA, IgA anti-tTA (tissue transglutarnin ase 
antibodies), 
At all subsequent time points: dearn.ida ted gliadin peptide antibodies (anti-DGP IgA or IgG); Anti -endomy sial antibodies (EMA ), RF, CCP , dsDNA, ANA, S SA, SSB , IgA 
anti-tTA (tissue transglutantin ase antibodie s), 
o As outline in Appendix 6 
p PK sample s will be collected prior to study dmg admini stration (pre-d ose) at Weeks 4, 8, 12, 24, 36, and 48/ET visit. At Week 18, PK sample s will be collec ted 
. tl21 t d I 
• 
• • : •,I~ • " : • :.: .. • pj y p ' p q p p g 
to be done if and when the materi al is available at site. 
s p 
, . . . . t ,,, p ,,, ty pp ment of ocular, oral 
dtyn ess, vaginal dtyne ss (if applic able) assessment of pain, fatigue , 
u If available in tlte prima1y language of the subjec t. Questionna!fe s a · e ssmg 1 sease, activi ty an fatigue may be prnvided when and where available. 
v PFT include s Spi[INVESTIGATOR_756926] . Subjec ts with the follo wing conti·aindic ations to s pi[INVESTIGATOR_756927]1fon11 the exam: nausea, vomiting , recen t stroke , eye stu·ge1y , 
thoracic/abdominal sm· e1 and recent neum othorax 
z mg, 
CONFIDENTIAL Page 108 12 July2 018 
Filgotinib , GS-9876 and GS-4059 
Protocol GS-US-445-4189 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
Appendix 3. Management of Clinical and Laboratory Adverse Events 
G1·adel 
.__ __ G_r_ad_e_2 __ __.I ... I ___ Gt_·_ad_e_3 __ __.l l ... ____ Gt_·a_d_e 4 ____ __, 
! ! 
!\fay continue dosing Repeat lab to Repeat lab to 
at the discretion of confin n toxicity confi rm. toxicity H confirmed and 
the innstigator gnde grade --+ possibly or probably 
1·elated to IMP, 
discontinue IMP 
dosing permanently 
and follow at pe1iodic 
inten-als at least 
H confirmed and possibly and/or probably related to IMP: H confirmed and unrelated to IMP, weekly until a return 
1. Withhold IMP until:, G1·ade 2 dosing may continue at the to baseline or is 
2. Restart IMP discretion of the investigator otherwise explained ..--l ,---------------------, 
H Grade 3 or 4 recu1Tence that is confu med and possibly or probably 
related to IMP, discontinue 11\IP dosing permanently 
See also Sections 3 .4 and 7. H Grade 3 or 4 rec,UJTence that is considered unrelated to IMP, 
continue 11\IP at the discretion of the innstigator 
CONFIDENTIAL Page 109 12 July 2018 
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 110 12July2018Appendix 4. Common Terminology Criteria f or Adverse Events (CTCAE) v4.03
CTCAE v4.03 can be accessed from the below link:
http://www.hrc.govt.nz/sites/default/file s/CTCAE%20manual%20 -%20DMCC.pdf
The only  modification to the CTCAE crit
eria is the addition of a Grade 1 upper respi[INVESTIGATOR_756928]:
CTCAE v4.0 Term Grade 1 Grade 2 Grade 3 Grade 4 Grade 5CTCAE v4.03 AE 
Term Definition
Upper respi[INVESTIGATOR_746114]; 
symptomatic relief 
(eg, cough 
suppressant, 
decongestant)Moderate 
symptoms; oral 
intervention 
indicated 
(egantibiotic, 
antifungal, antiviral)IV antibiotic, 
antifungal, or 
antiviral 
intervention 
indicated; 
radiologic, 
endoscopic, or 
operative 
intervention 
indicatedLife-threatening 
consequences; 
urgent intervention 
indicatedDeath A disorder 
characterized by [CONTACT_386049][INVESTIGATOR_4352] 
(nose, paranasal 
sinuses, pharynx, 
larynx, or trachea).
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 111 12July2018Appendix 5. Pregnancy Precautions, Definition ofFemale of Childbearing 
Potential, and Contraceptive Measures
For participation in this study , the use of 
highly effective contraception is required as outlined 
below for all subjects who are of childbearing potential.
1)Definitions
a.Definition of Female of Childbearing Potential
For the purposes of this study , afemale born subject is consi dered of childbearing potential
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal , 
unless permanentl y sterile or with medicall y documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 month s without an alternative cause. 
Inaddition, women of any  age with amenorrhea of > [ADDRESS_1036093] of an y age.
Also s ee I/E Criteria in Section 4.2.
b.Definition of Male Fertility
For the purposes of this study , amale -born subject is considered fertile unless permane ntly 
sterile by  [CONTACT_756953] y with docum entation of sperm -free ejaculate at least 
3month s afterthe procedure .Other t ypes of document ed permanent infertility  may  be allowed, 
after discussion with the Sponsor and approval in writing.
2)Contraception for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Filgotinib is contraindicated in pregnancy as there is a possibility  of human 
teratogenicit y/fetotoxicity  in earl y pregnancy based on non- clinical data. Data from a drug -drug 
interaction study  of filgotinib and hormonal contraceptives demonstrated that filgotinib does not 
alter the pharmacokinetics of representative hormonal contraceptives levonorgestrel/ethin yl 
estradiol. 
GS-[ADDRESS_1036094] findings that raise a 
strong suspi[INVESTIGATOR_756929] /fetotoxicity . In vitro drug interaction assessment of 
GS-9876 and hormonal contraceptives suggests that ther e is no clinicall y relevant effects that 
would decrease contraception efficacy . 
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 112 12July2018GS-4059 is contraindicated in pregnancy  as its teratogenicity /fetotoxicity  profile is unknown. 
GS-[ADDRESS_1036095] dose of stud y drug.
Complete abstinence from intercou rse of rep
roductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine devic e (IUD) with a failure rate of < 1% per y ear
Tubal sterilization
Ensure micro -insert sy stem (provided confirmation of success 3 month s after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 month s after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 36days after the last dose of study  drug.
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 113 12July20183)Contraception for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid. Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until [ADDRESS_1036096] dose of study  drug .
4)Unacceptable Methods of Birth Control
Birth control methods that are unacceptable include periodic abstinence ( including calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), useof 
spermicides 
alone , and lactational amenorrhea method (LAM). The f emale condom and male 
condom should not be used together.
5) Procedures to be Followed in the Event of Pregnancy
Female s ubjects will be instructed to notify  the investigator if they  become pregnant at an y time 
during the study, or within [ADDRESS_1036097] 
dose of study  drug ,are to report the information to the 
investigator.
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section [IP_ADDRESS].
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 114 12July2018Appendix 6. Laboratory Assessment Table
Hem atology Chemistry Urinalysis Other
Hem atocrit
Hem oglobin
Platelet count
Red blood cell (RBC) 
count
WBC count
Differentials (absolute 
and percentage), 
including:
Leucocytes
Monocytes
Neutrophils
Eosinophils
Basophils
Mean corpuscular 
volume (MCV)
INRAlkaline phosphatase
Aspartate aminotransferase 
(AST)
Alanine aminotransferase 
(ALT)
Gamma -glutamyl 
transpeptidase (GGT)
Total bilirubin
Direct and indirect 
bilirubin
Total protein
Albumin
Bicarbonate
Blood urea nitrogen 
(BUN)
Calcium
Chloride
Serum creatinine
Glucose
Phosphorus
Magnesium
Potassium
Sodium
Amylase
Lipase
Lipid profile:
Triglycerides
Cholesterol and its 
subfractions (high -density 
lipoprotein [HDL] and 
low-density lipoprotein 
[LDL])
Leptin
LDL particle
Hom ocysteine
Apo A1/BAppearance
Blood
Color
Glucose
Leukocyte esterase
pH
Protein
Urobilinogen
Reflex to microscopic 
urinalysis if dips tick result 
is abnormal.Urine drug screen for:
Amphetamines
Cocaine
Methadone
Opi[INVESTIGATOR_858]
C-reactive protein (hsCRP)
QuantiFERON -TB GOLD
and other test as outlined in 
Schedule of assessment
Endocrine at screening 
onlySerology Pregnancy
Hem oglobin A1c
TSH
FSH (see Appendix 5)Hepatitis BsAg , Hepatitis 
B surface antibody and 
core Ab
Hepatitis C Ab (if positive 
reflex HCV RNA)
HIV antibodiesIn females of childbearing
potential:
Serum β -hCG ( at screening 
and if positive urine β -hCG)
Urine β -hCG (all other visits)†
† During the periods where visits are every [ADDRESS_1036098] monthly home pregnancy tests every 
4weeks; the site will contact [CONTACT_756954].
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 115 12July2018Appendix 7. American European Consensus Group (AECG)
Vitali C, et al. 
Classification criteria for Sjogren’s syndrome: a revised version of the 
European criteria proposed by [CONTACT_317921] -European Consensus Group. Ann Rheum Dis 
2002; 61:554-558.
I. Ocular s ymptoms: a positive response to at least one of the following questions:
1)Have you had daily, persistent, troublesome dry  eyes for more than 3 month s?
2)Do y ou have a recurrent sensation of sand or gravel in the ey es?
3)Do y ou use tear substitutes more than 3 times a day?
II. Oral s ymptoms: a positive response to at least one of the following questions:
4)Have you had a daily feeling of dr y mouth for more than 3 month s?
5)Have you had recurrentl y or persistently swollen salivary  glands as an adult?
6)Do y ou frequently  drink liquids to aid in swallowing dry food?
III. Ocular signs —that is, objective evidence of ocular involvement defined as a positive result 
for at least 
one of the following two tests:
1) Schirmer's I test, performed without anaesthesia (≤ 5 mmin 5minutes)
2) Rose bengal score or other ocular d ye score ( ≥4 according to van Bijsterveld 's scoring 
system)
IV.Histopathology :In minor salivary  glands (obtained through normal -appearing mucosa) 
focal lymphocy tic sialoadenitis, evaluated by  [CONTACT_756955], with a focus score 
≥1, defined as a number of ly mphocy tic foci (which are adjacent to normal -appearing 
mucous aci ni and contain more than 50 ly mphocy tes) per 4 mm2 of glandular tissue18
V. Salivary  gland involvement: objective evidence of salivary  gland involvement defined by  a 
positive result for at least one of the following diagnostic tests:
1) Unstimulated whole saliva ry flow ( ≤1.5 ml in 15 minutes)
2)Parotid sialograph y showing the presence of diffuse sialectasias (punctate, cavitary or 
destructive pattern), without evidence of o bstruction in the major ducts19
3)Salivary  scintigraphy  showing delay ed uptake, reduced concentration and/o r delay ed 
excretion of tracer20
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 116 12July2018VI. Autoantibodies: presence in the serum of the following autoantibodies:
1) 1. Antibodies to Ro(SSA) or La(SSB) antigens, or both
For primary  SjS:
In patients without any  potentially  associated disease, primary  SjS may  be defined as follows:
a)The presence of an y 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology ) or VI (Serology ) is positive
b)The presence of an y 3 of the 4 objective criteria items (that is, items III, IV, V, VI)
c)The classification tree procedure represents a valid alternative method for classification, 
although it should be more properly  used in clinical -epi[INVESTIGATOR_756930]:
In patients with a potentially  associated disease (for instance, another well -defined connective 
tissue disease), the presence of item I or item II plus any  2 from among items III, IV, and V may  
be considered as indicative of secondary  SjS.
Exclusion criteria: 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency  disease (AIDS) 
Pre-existing ly mphoma 
Sarcoidosis 
Graft versus host disease 
Use of anticholinergic drugs (since a time shorter than 4- fold the half -life of the drug).
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 117 12July2018Appendix 8. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI)
Seror R, Bowman SJ, Brito
-Zeron P,et al. EULAR Sjögren’s syndrome disease activity 
index (ESSDAI): a user guide. RMD Open 2015;1:e000022. doi: 10.1136/rmdopen-2014-
000022
Domain Activity Level Description
Constitutional
Exclusion of fever of infectious origin
and voluntary weight lossNo= 0 Absence of the following symptoms
Low = 3 Mild or intermittent fever (37.5° –38.5°C)/night sweats and/or involuntary 
weight loss of 5 to 10% of body weight
Moderate = 6 Severe fever (>38.5°C)/night sweats and/or involuntary weight loss of 
>10% of body weight
Lymphadenopathy and lymphoma
Exclusion of infectionNo= 0 Absence of the following features
Low = 4 Lymphadenopathy ≥ 1 cm in any nodal region or ≥ 2 cm in inguinal 
region
Moderate = 8 Lymphadenopathy ≥ 2 cm in any nodal region or ≥ 3 cm in inguinal 
region, and/or splenomegaly (clinically palpable or assessed by [CONTACT_9661])
High =12 Current malignant B -cell proliferative disorder
Glandular
Exclusion of stone or infectionNo= 0 Absence of glandular swelling
Low = 2 Small glandular swelling with enlarged parotid ( ≤ 3 cm), or limited 
submandibular (<2 cm) or lachrymal swelling (<1 cm)
Moderate = 4 Major glandular swelling with enlarged parotid (> 3 cm), or important 
submandibular or lachrymal swelling
Articular
Exclusion of osteoarthritisNo= 0 Absence of currently active articular involvement
Low = 2 Arthralgias in hands, wrists, ankles and feet accompanied by [CONTACT_756956] (>30 min)
Moderate = 4 1 to 5 (of 28 total count) synovitis
High = 6 ≥ 6 (of 28 total count) synovitis
Cutaneous
Rate as “No activity” stable long -lasting
features related to damageNo= 0 Absence of currently active cutaneous involvement
Low = 3 Erythema multiforma
Moderate = 6 Limited cutaneous vasculitis, including urticarial vasculitis, or purpura 
limited to feet and ankle, or subacute cutaneous lupus
High = 9 Diffuse cutaneous vasculitis, including urticarial vasculitis, or diffuse 
purpura, or ulcers related to vasculitis
Pulmonary
Rate as “No activity” stable long -lasting
features related to damage, or 
respi[INVESTIGATOR_756931] (tobacco use, etc.)No= 0 Absence of currently active pulmonary involvement
Low = [ADDRESS_1036099] evidence of interstitial lung disease with: No 
breathlessness and normal lung function test.
Moderate =[ADDRESS_1036100] with shortness of breath on exercise (NHYA II) 
or abnormal lung function tests restricted to: 70% >DL co≥ 40% or 80% 
>FVC ≥60%
High =[ADDRESS_1036101] (NHYA III, IV) or with 
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 118 12July2018abnormal lung function tests: DL co<40% or FVC < 60%
FVC, forced vital capacity: HRCT high -resolution CT; NYHA [LOCATION_001] Heart Association.
Renal
Rate as “No activity” stable long -lasting 
features related to damage, and renal 
involvement not related to the disease.
If biopsy has been performed, please
rate activity based on histological 
features firstNo= 0 Absence of currently active renal involvement with 
proteinuria< 0.5g/day, no h aematuria, no leucocyturia, no acidosis, or 
long-lasting stable proteinuria due to damage
Low = 5 Evidence of mild active renal involvement, limited to tubular acidosis 
without renal failure or glomerular involvement with proteinuria (between 
0.5 and 1 g/day) and without h aematuria or renal failure (GFR ≥60 
ml/min)
Moderate =10 Moderately active renal involvement, such as tubular acidosis with renal 
failure (GFR <60 ml/min) or glomerular involvement with proteinuria 
between 1 and 1.5 g/dayand without ha ematuria or renal failure (GFR 
≥60 ml/min) or histological evidence of extra- membranous 
glomerulonephritis or important interstitial lymphoid infiltrate
High =15 Highly active renal involvement, such as glomerular involvement with 
proteinuria >1.5 g/dayor haematuria or renal failure (GFR <60 ml/min), 
or histological evidence of proliferative glomerulonephritis or 
cryoglobulinemia related renal involvement
GFR, glom erular filtration rate.
Muscular
Exclusion of weakness due to
corticosteroidsNo= 0 Absence of currently active muscular involvement
Low = 6 Mild active myositis shown by [CONTACT_410867] , MRI* or biopsy with no 
weakness and creatine kinase (N <CK ≤ 2N)
Moderate =12 Moderately active myositis proven by [CONTACT_410867] , MRI* or biopsy 
with weakness (maximal deficit of 4/5), or elevated creatine kinase (2N <
CK ≤4N),
High =18 Highly active myositis shown by [CONTACT_410867] , MRI* or biopsy with 
weakness (deficit ≤ 3/5) or elevated creatine kinase (>4N)
*We decided to add this item not included in the initial version since the value of this examination for the diagnosis of myo sitis was not 
clear until recently.                                                                                                                                                                                                          
EMG electromyogram.
PNS
Rate as “No activity” stable long -lasting
features related to damage or PNS 
involvement not related to the diseaseNo= 0 Absence of currently active PNS involvement
Low = 5 Mild active PNS involvement, such as pure sensory axonal 
polyneuropathy shown by [CONTACT_756957] (V) neuralgia              
*Proven small fib reneuropathy
Moderate =10 Moderately active PNS involvement shown by [CONTACT_410869], such as axonal 
sensory -motor neuropathy with maximal motor deficit of 4/5, pure 
sensory neuropathy with presence of cryoglobulinemic vasculitis, 
ganglionopathy with symptoms restricted to mild/moderate ataxia, 
inflammatory demyelinating polyneuropathy (CIDP) with mild functional 
impairment (maximal motor deficit of 4/5or mild ataxia),
Or cranial nerve involvement of peripheral origin (except trigem inal (V) 
neuralgia)
High =15 Highly active PNS involvement shown by [CONTACT_410869], such as axonal sensory -
motor neuropathy with motor deficit ≤3/5, peripheral nerve involvement 
due to vasculitis (mononeuritis multiplex ,etc.), severe ataxia due to 
ganglionopathy, inflammatory demyelinating polyneuropathy (CIDP) with 
severe functional impairment: motor deficit ≤3/5 or severe ataxia
Filgotinib, GS -9876 and GS -4059
Protocol GS –US-445-4189 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 119 12July2018*We decided to add this item not included in the initial version since the link between this entity and SS was not clear unti l recentl y. 
CIDP, chronic inflammatory demyelinating polyneuropathy; NCS nerve conduction study.
CNS
Rate as “No activity” stable long -lasting
features related to damage or CNS 
involvement not related to the diseaseNo= 0 Absence of currently active CNS involvement
Moderate =10 Moderately active CNS features, such as cranial nerve involvement of 
central origin, optic neuritis or multiple sclerosis -like syndrome with 
symptoms restricted to pure sensory impairment or proven cognitive 
impairment
High =[ADDRESS_1036102] be considered Exclusion 
of vitamin or iron deficiency, 
drug -induced cytopeniaNo= 0 Absence of auto -immune cytopenia
Low = 2 Cytopenia of auto -immune origin with neutropenia (1000 < neutrophils <
1500/mm3), and/or an aemia (10 < haemoglobin <12g/dL), and/or 
thrombocytopenia (100,000 <platelets <150,000/mm3)
Or lymphopenia (500 <lymphocytes <1000/mm3)
Moderate = 4 Cytopenia of auto -immune origin with neutropenia (500 ≤ neutrophils ≤ 
1000/mm3), and/or an aemia (8 ≤ haemoglobin ≤ 10 g/dL), and/or 
thrombocytopenia (50,000 ≤ platelets ≤ 100,000/mm3)
Or lymphopenia ( ≤500/mm3)
High = 6 Cytopenia of auto -immune origin with neutropenia (neu trophils 
<500/mm3), and/or or an aemia (h aemoglobin < 8g/dL) and/or 
thrombocytopenia (platelets <50,000/mm3)
Biological No= 0 Absence of any of the following biological feature
Low = 1 Clonal component and/or hypocomplementemia (low C4 or C3 or CH50) 
and/or hypergammaglobulinemia or high IgG level between 16 and 20 g/L
Moderate = 2 Presence of cryoglobulinemia and/or hypergammaglobulinemia or high 
IgG level > 20 g/L, and/or recent onset hypogammaglobulinemia or recent 
decrease of IgG level (<5 g/L)
CIDP= chronic inflammatory demyelinating polyneuropathy; CK= creatine kinase; CNS= central nervous system; DLCO= 
diffusing CO capacity; EMG= electromyogram; FVC= forced vital capacity; GFR= glomerular filtration rate; Hb= hemoglobin ; 
HRCT= high -resolution computed tomography; IgG= immunoglobulin G; NCS= nerve conduction studies; NHYA= [LOCATION_001] 
heart association classification; Plt= platelet; PNS=peripheral nervous system